## metadata
source file: data/floodlamp/reg/fda-townhalls/f5_fixnames/run_auto/2020-05-06_Virtual Town Hall 7_fixnames.md
last updated: 2024-12-31 Created QA Sections
link pdf: https://www.fda.gov/media/137986/download?attachment
link youtube: https://youtu.be/4J2HEZvqjT4
link slides: 
topic: COVID-19


## content

### qa


#### 1. FDA Updates on COVID-19 Serological Testing Guidelines

QA Block 1-1
CLARIFIED QUESTION: What are the details of the FDA's updated antibody test policy for commercial manufacturers?
CLARIFIED ANSWER: The FDA updated its policy for COVID-19 antibody tests, requiring commercial manufacturers to submit emergency use authorization requests with validation within 10 days of notifying the FDA or the policy publication date.
VERBATIM QUESTION: What are the details of the FDA's updated antibody test policy for commercial manufacturers?
VERBATIM ANSWER: That's why earlier this week we did update our policy and guidance on COVID-19 antibody tests. Most notably we are changing the policy as it applies to commercial manufacturers, those kit developers out there right now. Under this new policy, the FDA has outlined expectations for antibody test developers, including of course kit manufacturers, which will - who will submit emergency use authorization requests with their validation within ten days from the date they either notify the FDA of their validation testing or from the date of the publication of the policy, which was Monday this week, whichever is later.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA antibody test policies, Emergency Use Authorization, Validation requirements
REVIEW FLAG: False

QA Block 1-2
CLARIFIED QUESTION: What validation and performance expectations must be submitted for serological tests under the new policy?
CLARIFIED ANSWER: The new FDA guidance requires serological test developers, including kit manufacturers, to submit EUA requests with validation results within ten days. Performance expectations include overall sensitivity of 90% and specificity of 95%; for broken-down isotypes, IgG sensitivity must be at least 90% and IgM at least 70%, with specificity remaining at 95%.
VERBATIM QUESTION: What validation and performance expectations must be submitted for serological tests under the new policy?
VERBATIM ANSWER: Under this new policy, the FDA has outlined expectations for antibody test developers, including of course kit manufacturers, which will - who will submit emergency use authorization requests with their validation within ten days from the date they either notify the FDA of their validation testing or from the date of the publication of the policy, which was Monday this week, whichever is later. ... So at a high level, the performance expectation for serological tests going forward is that the overall sensitivity, whether it's not broken up isotype or a single is a single isotype of combined is 90%, 9-0 percent. And the combined or overall specificity should be at least 95%. If isotypes broken out, the expectation is that the specificity should be at least 95% per each isotype and then sensitivity, the expectation is that IgG, if reported out separately, would have a sensitivity of at least 90% and then if IgM is reported out separately, that the sensitivity for IgM remains at - should be at 70%.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serological test validation, Performance expectations, EUA submission timeline
REVIEW FLAG: False

QA Block 1-3
CLARIFIED QUESTION: What is the timeline for submitting emergency use authorization requests for antibody tests under the new guidance?
CLARIFIED ANSWER: Under the new policy, antibody test developers are expected to submit emergency use authorization (EUA) requests with validation within 10 days of notifying FDA of validation testing or from the policy's publication date, whichever is later.
VERBATIM QUESTION: What is the timeline for submitting emergency use authorization requests for antibody tests under the new guidance?
VERBATIM ANSWER: Under this new policy, the FDA has outlined expectations for antibody test developers, including of course kit manufacturers, which will - who will submit emergency use authorization requests with their validation within ten days from the date they either notify the FDA of their validation testing or from the date of the publication of the policy, which was Monday this week, whichever is later.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antibody test EUA timeline, Validation submission, New FDA guidance
REVIEW FLAG: False

QA Block 1-4
CLARIFIED QUESTION: What changes were made to the regulatory flexibility originally provided to serological test developers?
CLARIFIED ANSWER: The FDA updated its policy by requiring commercial manufacturers of serological tests to submit emergency use authorization requests with validation within ten days. Originally, regulatory flexibility was provided during the emergency, but the policy has now been revised to include specific performance expectations.
VERBATIM QUESTION: What changes were made to the regulatory flexibility originally provided to serological test developers?
VERBATIM ANSWER: That's why earlier this week we did update our policy and guidance on COVID-19 antibody tests. Most notably we are changing the policy as it applies to commercial manufacturers, those kit developers out there right now. Under this new policy, the FDA has outlined expectations for antibody test developers, including of course kit manufacturers, which will - who will submit emergency use authorization requests with their validation within ten days from the date they either notify the FDA of their validation testing or from the date of the publication of the policy, which was Monday this week, whichever is later. When we issued our original serological test policy in mid-March, it was critical that the FDA provide regulatory flexibility for serological test developers, given the nature of the public health emergency and also the understanding that tests were not to be used for COVID-19 diagnosis, a fact that remains true until today and through today. We have authorized quite a few serological tests now through the EUA process and so really at this time it was appropriate to take another look at that policy and to make a change. And that change is of course, as mentioned, that we expect all kit manufacturers to come in within the ten-day period, and our performance expectations are also laid out in this updated policy guidance.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Regulatory updates for serological tests, Emergency Use Authorizations, Performance expectations
REVIEW FLAG: False

QA Block 1-5
CLARIFIED QUESTION: What are the specific performance thresholds for sensitivity and specificity for serological tests going forward?
CLARIFIED ANSWER: The FDA's performance expectations for serological tests are at least 90% overall sensitivity and at least 95% overall specificity. If isotypes are separated, specificity remains at 95% for each isotype. Sensitivity should be at least 90% for IgG and 70% for IgM.
VERBATIM QUESTION: What are the specific performance thresholds for sensitivity and specificity for serological tests going forward?
VERBATIM ANSWER: So at a high level, the performance expectation for serological tests going forward is that the overall sensitivity, whether it's not broken up isotype or a single is a single isotype of combined is 90%, 9-0 percent. And the combined or overall specificity should be at least 95%. If isotypes broken out, the expectation is that the specificity should be at least 95% per each isotype and then sensitivity, the expectation is that IgG, if reported out separately, would have a sensitivity of at least 90% and then if IgM is reported out separately, that the sensitivity for IgM remains at - should be at 70%.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serological test performance, sensitivity and specificity thresholds, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 1-6
CLARIFIED QUESTION: What are the FDA's recommendations for confirmatory serological testing when specificity is a concern?
CLARIFIED ANSWER: The FDA recommends using a second confirmatory serological test with a different antigen to improve specificity, potentially enhancing the likelihood of true positives. However, even two tests may yield combined false positives as no test is entirely specific.
VERBATIM QUESTION: What are the FDA's recommendations for confirmatory serological testing when specificity is a concern?
VERBATIM ANSWER: As has been mentioned previously, if it's important to know whether an antibody test really is specific that a second confirmatory serological test utilizing a different antigen should be considered as well. The combined dual-positive results requirement, if you follow that path, if you choose to follow that path, greatly - has the potential to greatly increase the specificity. In the end, it does increase substantially, in theory, the positive predictive value of a positive result that is the likelihood that a positive result is a true positive. There's still the chance that it - that even after two serological tests you could still have a combined false positive result, given that few, if any, tests are 100% specific. However, this confirmation test, if used, should greatly increase the predictive power of serological tests, if that's important for a given patient or for a population study.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Confirmatory serological testing, Specificity improvement, Dual-positive results
REVIEW FLAG: False

QA Block 1-7
CLARIFIED QUESTION: What factors will the FDA consider in making regulatory determinations for serological tests, including data sources?
CLARIFIED ANSWER: The FDA considers the totality of evidence for serological tests, including data from test developers, results from NCI testing, publications, and government agency reports.
VERBATIM QUESTION: What factors will the FDA consider in making regulatory determinations for serological tests, including data sources?
VERBATIM ANSWER: When we make regulatory decisions going forward around serological tests we will of course as always take in the totality of the evidence, presented both by the test developer, if testing is done at NCI, those results, and other information that we may glean about the performance of a given test. That may be publications, reports from other government agencies, et cetera.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serological test regulatory decisions, data sources for test evaluation
REVIEW FLAG: False

QA Block 1-9
CLARIFIED QUESTION: What new updates did the FDA add to the FAQ page regarding molecular testing and the screening of asymptomatic individuals?
CLARIFIED ANSWER: The FDA updated its FAQ page regarding molecular testing, stating that most EUA-authorized SARS-CoV-2 molecular diagnostics are for individuals suspected of COVID-19. Testing asymptomatic individuals is at the healthcare provider's discretion. Tests must be validated for the intended population. Developers interested in screening asymptomatic individuals should contact FDA for validation guidance.
VERBATIM QUESTION: What new updates did the FDA add to the FAQ page regarding molecular testing and the screening of asymptomatic individuals?
VERBATIM ANSWER: I did want to briefly mention that we added other updates to our FAQ page. We have updated the page to address of molecular tests at least, the testing or screening of a symptomatic individual. So that should have been posted already. And so the question has been frequent and so we wanted to post the answer that we've come up with. At this time most EUA-authorized SARS-CoV2 molecular diagnostics are authorized for use in individual suspected of COVID-19 by their health care providers. Testing of asymptomatic individuals who are suspected of COVID-19 are is at the discretion of the health care provider ordering the test. All tests should be appropriately validated for the intended use population. If you would like to develop and offer a test with an intended use, including board screening of any asymptomatic individuals, please reach out to our templates email address to discuss the validation necessary to support an EUA for such an indication or claim for performance of your test in an asymptomatic population.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FAQ updates, molecular testing, asymptomatic individual screening
REVIEW FLAG: False

QA Block 1-10
CLARIFIED QUESTION: What steps should developers take if they want to validate tests for broader screening of asymptomatic populations?
CLARIFIED ANSWER: FDA advises developers to contact their templates email address to discuss validation requirements for obtaining EUA for tests intended for broader screening of asymptomatic populations.
VERBATIM QUESTION: What steps should developers take if they want to validate tests for broader screening of asymptomatic populations?
VERBATIM ANSWER: At this time most EUA-authorized SARS-CoV2 molecular diagnostics are authorized for use in individual suspected of COVID-19 by their health care providers. Testing of asymptomatic individuals who are suspected of COVID- 19 are is at the discretion of the health care provider ordering the test. All tests should be appropriately validated for the intended use population. If you would like to develop and offer a test with an intended use, including board screening of any asymptomatic individuals, please reach out to our templates email address to discuss the validation necessary to support an EUA for such an indication or claim for performance of your test in an asymptomatic population.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Test validation for asymptomatic populations, EUA requirements
REVIEW FLAG: False

QA Block 1-11
CLARIFIED QUESTION: Where can developers find the serological test development templates provided by the FDA?
CLARIFIED ANSWER: Developers can find the serological test development templates for both kit manufacturers and laboratories in an editable format on the FDA's website.
VERBATIM QUESTION: Where can developers find the serological test development templates provided by the FDA?
VERBATIM ANSWER: And one other update is that we did provide serological tests development templates for both IVD kit manufacturers as well as laboratories who develop a test and that is downloadable in editable form to make it easy to use. So please check out our website.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serological test development templates, FDA resources
REVIEW FLAG: False

QA Block 1-12
CLARIFIED QUESTION: What is the purpose of the new FDA calculator for estimating test performance, and how can it be used effectively?
CLARIFIED ANSWER: The FDA calculator is a tool for estimating test performance by inputting sensitivity, specificity, and prevalence for single or two-test strategies. Although not validated, it provides useful performance predictions.
VERBATIM QUESTION: What is the purpose of the new FDA calculator for estimating test performance, and how can it be used effectively?
VERBATIM ANSWER: On the EUA authorized serological test performance website in the FDA we now list a calculator that you may use. This calculator allows you to input test performance, either a single test prevalence for your population and if you're going to use a two-test strategy, you can put in the performance, the sensitivity specificity - calculated sensitivity specificity for the assay, along with the prevalence and it will give you the combined performance as predicted. This is not actually because we have not validated the actual performance with two tests but it is a potentially useful tool to try to get an estimated performance of either a single test or two independent tests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA serological calculator, test performance estimation, use of sensitivity/specificity inputs
REVIEW FLAG: False


#### 2. Human Factors Testing and Simulated Use in Diagnostics

QA Block 2-1
CLARIFIED QUESTION: Do you agree or disagree with the approach described in my comments regarding ease of use and human factors testing?
CLARIFIED ANSWER: The FDA is reviewing this and will ensure alignment with its human factors group. Templates are being developed for home collection and testing, with an emphasis on accuracy and safe use.
VERBATIM QUESTION: Do you agree or disagree with the approach described in my comments regarding ease of use and human factors testing?
VERBATIM ANSWER: So great questions. You know, in an attempt to adequately address this emergency and to make sure that as we move into home collection or home testing that we ensure the accuracy of those tests, we are taking steps to try to assure this through the accumulation of data to justify that these technologies can be accurately used. So I think the - I will double-check with our team, although I'm sure they're familiar with the human factors group at the FDA and make sure that we are aligned, to the extent we can, under this emergency and I think that that's a good thing for me to check on. We are working on a template for home collection. We hope to make that available in the not-too-distant future. We will then turn our attention - and we also are working on an antigen, a direct antigen template, and then after those we will begin working on the likelihood that we will be seeing home tests applications as well. So we'll turn our attention to developing a template for that to help developers as well.
SPEAKER QUESTION: Shannon Clark
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Ease of use testing, Human factors alignment, Templates for home diagnostics
REVIEW FLAG: False

QA Block 2-2
CLARIFIED QUESTION: What is your position on using simulated use assessments where users simulate certain actions, such as administering a finger stick, instead of using real samples in human factors testing?
CLARIFIED ANSWER: The FDA remains open to simulated use assessments but currently prioritizes tests conducted with actual or simulated patients to ensure safety and accuracy during the emergency.
VERBATIM QUESTION: What is your position on using simulated use assessments where users simulate certain actions, such as administering a finger stick, instead of using real samples in human factors testing?
VERBATIM ANSWER: We're open to taking a look at that. At this moment when we require so little relative to our normal procedure of data, we do want to make sure that these things are appropriate. We have seen a lay and patient and consumer test results from the methods that we're using now and we know that not all users may follow a given set of directions very well. And so our attempts really twofold. One is to ensure the safety of the process and the second is the accuracy of the process. And at the moment, while we remain open to these other suggestions, we feel it's important to assess this performance right now in this emergency with actual patients or simulated patients.
SPEAKER QUESTION: Shannon Clark
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Simulated use assessments, Human factors testing, Emergency testing requirements
REVIEW FLAG: False

QA Block 2-3
CLARIFIED QUESTION: What level of alignment exists between the FDA's various teams, such as the human factors group, regarding guidance for home-based COVID-19 diagnostics?
CLARIFIED ANSWER: FDA will confirm alignment with its human factors group and ensure consistent guidance during the emergency period. They are also developing templates for home collection and home test applications.
VERBATIM QUESTION: What level of alignment exists between the FDA's various teams, such as the human factors group, regarding guidance for home-based COVID-19 diagnostics?
VERBATIM ANSWER: You know, in an attempt to adequately address this emergency and to make sure that as we move into home collection or home testing that we ensure the accuracy of those tests, we are taking steps to try to assure this through the accumulation of data to justify that these technologies can be accurately used. So I think the - I will double-check with our team, although I'm sure they're familiar with the human factors group at the FDA and make sure that we are aligned, to the extent we can, under this emergency and I think that that's a good thing for me to check on. We are working on a template for home collection. We hope to make that available in the not-too-distant future. We will then turn our attention - and we also are working on an antigen, a direct antigen template, and then after those we will begin working on the likelihood that we will be seeing home tests applications as well. So we'll turn our attention to developing a template for that to help developers as well.
SPEAKER QUESTION: Shannon Clark
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA team alignment, home-based diagnostics, guidance development
REVIEW FLAG: False

QA Block 2-4
CLARIFIED QUESTION: Will the upcoming template for home collection address specific usability data requirements for these tests?
CLARIFIED ANSWER: FDA is working on a template for home collection tests, which will be available soon. After this, FDA will focus on templates for antigen tests and future home test applications to support developers.
VERBATIM QUESTION: Will the upcoming template for home collection address specific usability data requirements for these tests?
VERBATIM ANSWER: We are working on a template for home collection. We hope to make that available in the not-too-distant future. We will then turn our attention - and we also are working on an antigen, a direct antigen template, and then after those we will begin working on the likelihood that we will be seeing home tests applications as well. So we'll turn our attention to developing a template for that to help developers as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: home collection, usability data, template development
REVIEW FLAG: False

QA Block 2-5
CLARIFIED QUESTION: How does the FDA plan to ensure accuracy and safety for home-based COVID-19 testing during the emergency use period?
CLARIFIED ANSWER: FDA is ensuring accuracy and safety for home tests through data accumulation to validate technology use. A template for home collection tests is being developed, and further work for home test templates is planned.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: In an attempt to adequately address this emergency and to make sure that as we move into home collection or home testing that we ensure the accuracy of those tests, we are taking steps to try to assure this through the accumulation of data to justify that these technologies can be accurately used. So I think the - I will double-check with our team, although I'm sure they're familiar with the human factors group at the FDA and make sure that we are aligned, to the extent we can, under this emergency and I think that that's a good thing for me to check on. We are working on a template for home collection. We hope to make that available in the not-too-distant future. We will then turn our attention - and we also are working on an antigen, a direct antigen template, and then after those we will begin working on the likelihood that we will be seeing home tests applications as well. So we'll turn our attention to developing a template for that to help developers as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Home COVID-19 testing, Accuracy and safety, FDA guidelines
REVIEW FLAG: False

QA Block 2-6
CLARIFIED QUESTION: Does the FDA consider simulated use assessments sufficient for validating certain types of human factor elements in diagnostics, like instructions for use or finger stick administration?
CLARIFIED ANSWER: FDA is open to considering simulated use assessments but emphasizes the need for ensuring safety and accuracy, particularly during the emergency. Currently, they prefer evaluations involving actual or simulated patients rather than solely relying on simulated use.
VERBATIM QUESTION: Does the FDA consider simulated use assessments sufficient for validating certain types of human factor elements in diagnostics, like instructions for use or finger stick administration?
VERBATIM ANSWER: We're open to taking a look at that. At this moment when we require so little relative to our normal procedure of data, we do want to make sure that these things are appropriate. We have seen a lay and patient and consumer test results from the methods that we're using now and we know that not all users may follow a given set of directions very well. And so our attempts really twofold. One is to ensure the safety of the process and the second is the accuracy of the process. And at the moment, while we remain open to these other suggestions, we feel it's important to assess this performance right now in this emergency with actual patients or simulated patients.
SPEAKER QUESTION: Shannon Clark
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Simulated use assessments, Human factor validation, Emergency assessment procedures
REVIEW FLAG: False

QA Block 2-7
CLARIFIED QUESTION: What justifies the FDA's current preference for performance data involving actual patients or simulated patients over alternative assessment methods?
CLARIFIED ANSWER: The FDA prioritizes data from actual or simulated patients to ensure safety and accuracy during this emergency since lay users may not properly follow directions.
VERBATIM QUESTION: What justifies the FDA's current preference for performance data involving actual patients or simulated patients over alternative assessment methods?
VERBATIM ANSWER: We're open to taking a look at that. At this moment when we require so little relative to our normal procedure of data, we do want to make sure that these things are appropriate. We have seen a lay and patient and consumer test results from the methods that we're using now and we know that not all users may follow a given set of directions very well. And so our attempts really twofold. One is to ensure the safety of the process and the second is the accuracy of the process. And at the moment, while we remain open to these other suggestions, we feel it's important to assess this performance right now in this emergency with actual patients or simulated patients.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA preference for patient data, Safety and accuracy, Emergency testing protocols
REVIEW FLAG: False


#### 3. CLIA Waivers and Point-of-Care Testing Regulations

QA Block 3-1
CLARIFIED QUESTION: Does the FDA object to the use of IVDD serology antibody rapid tests outside of a laboratory by health care professionals?
CLARIFIED ANSWER: The FDA requires IVDD serology antibody rapid tests to be performed under a CLIA certificate of waiver situation, even for point-of-care use.
VERBATIM QUESTION: Does the FDA object to the use of IVDD serology antibody rapid tests outside of a laboratory by health care professionals?
VERBATIM ANSWER: It's our understanding that these tests should, even if they're point of care, near-patient, they should be performed in - under a CLIA certificate of waiver situation. So that's about all I can say.
SPEAKER QUESTION: Tim Salter
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: IVDD serology antibody tests, CLIA certificate of waiver, Point-of-care testing
REVIEW FLAG: False

QA Block 3-2
CLARIFIED QUESTION: Am I understanding correctly that places like doctor's offices or urgent care clinics without a CLIA license cannot use point-of-care rapid tests?
CLARIFIED ANSWER: FDA cannot confirm whether places like doctor's offices or urgent care clinics can use point-of-care rapid tests without a CLIA license. This falls under CMS's regulatory oversight.
VERBATIM QUESTION: Am I understanding correctly that places like doctor's offices or urgent care clinics without a CLIA license cannot use point-of-care rapid tests?
VERBATIM ANSWER: There are actually, to my understanding, quite a few CLIA-waived sites in the US and I believe, and I would confirm with CMS, that they're very open for business and will work a provider to generate new certificates as may be FDA Townhall needed. And I guess, you know, it's not really a question that I can answer because that's not in our regulatory purview but it's in CMS's. We assess whether or not a test can be accurately performed outside of a high-complexity or moderately complex lab and then make the assessment about whether it can be a waived type test or a deemed waive test.
SPEAKER QUESTION: Tim Salter
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CLIA license requirements, Point-of-care testing, CMS regulatory role
REVIEW FLAG: False

QA Block 3-3
CLARIFIED QUESTION: At this point, is there any objection from the FDA for the use of these devices outside of the CLIA sphere?
CLARIFIED ANSWER: The FDA's understanding is that point-of-care or near-patient tests should be performed under a CLIA certificate of waiver.
VERBATIM QUESTION: At this point, is there any objection from the FDA for the use of these devices outside of the CLIA sphere?
VERBATIM ANSWER: It's our understanding that these tests should, even if they're point of care, near-patient, they should be performed in - under a CLIA certificate of waiver situation. So that's about all I can say.
SPEAKER QUESTION: Tim Salter
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CLIA certification, Point-of-care testing
REVIEW FLAG: False

QA Block 3-4
CLARIFIED QUESTION: Does the FDA view tests without EUA authorization as automatically designated for high-complexity lab use?
CLARIFIED ANSWER: The FDA designates tests without EUA authorization as high-complexity to ensure proper verification and validation in laboratories before use.
VERBATIM QUESTION: Does the FDA view tests without EUA authorization as automatically designated for high-complexity lab use?
VERBATIM ANSWER: So we make a - first of all those serological kit developers that have notified us if they have not received EUA authorizations, they are designated to be FDA Townhall high complexity. That was an important element of the prior policy to ensure that, to some degree, these tests that were not previously reviewed were performed in an excellent manner and also that the laboratory did perform their verification and their validation of those tests to ensure accuracy prior to putting them into service.
SPEAKER QUESTION: Tim Salter
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA authorization, high-complexity lab designation, test validation
REVIEW FLAG: False

QA Block 3-5
CLARIFIED QUESTION: What is the FDA's process for determining whether a point-of-care test can be used outside of moderate- or high-complexity labs?
CLARIFIED ANSWER: The FDA evaluates whether a point-of-care or near-patient test can be performed outside a moderately or high-complexity lab and designates it accordingly. Such tests generally require a CLIA waiver certificate, unless specifically authorized for home use; location decisions are guided by CMS requirements.
VERBATIM QUESTION: What is the FDA's process for determining whether a point-of-care test can be used outside of moderate- or high-complexity labs?
VERBATIM ANSWER: So when we review a potential point of care and near-patient test, we evaluate whether or not that test can be performed outside of a moderately or high- complexity lab and we so designate under this emergency in a way that allows for flexibility in where the tests can be performed. It is not, unless there's specific authorization for home use, it's not authorized for home use. That needs to be made clear. However, we do not as the FDA say exactly where a test should be performed. Rather there are other agency requirements that - and I would refer you to CMS and their recent information about this - but it's my understanding, and confirm with CMS, that if you're outside of a moderately or high-complexity lab, you do require a CLIA certificate to perform that, a CLIA-waiver certificate to perform that testing or the equivalent.
SPEAKER QUESTION: Tim Salter
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Point-of-care testing, FDA evaluation process, CLIA requirements
REVIEW FLAG: False

QA Block 3-6
CLARIFIED QUESTION: Are there any specific FDA regulatory requirements for point-of-care or near-patient tests to be performed without a CLIA waiver?
CLARIFIED ANSWER: The FDA states that point-of-care and near-patient tests should generally be performed under a CLIA certificate of waiver.
VERBATIM QUESTION: Are there any specific FDA regulatory requirements for point-of-care or near-patient tests to be performed without a CLIA waiver?
VERBATIM ANSWER: It's our understanding that these tests should, even if they're point of care, near-patient, they should be performed in - under a CLIA certificate of waiver situation. So that's about all I can say.
SPEAKER QUESTION: Tim Salter
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CLIA waiver requirements, Point-of-care tests, FDA regulations
REVIEW FLAG: False

QA Block 3-7
CLARIFIED QUESTION: Does the FDA allow for home use of tests without specific authorization?
CLARIFIED ANSWER: The FDA does not allow home use of tests unless specifically authorized.
VERBATIM QUESTION: Does the FDA allow for home use of tests without specific authorization?
VERBATIM ANSWER: It is not, unless there's specific authorization for home use, it's not authorized for home use. That needs to be made clear.
SPEAKER QUESTION: Tim Salter
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: home use authorization, FDA test regulation
REVIEW FLAG: False

QA Block 3-8
CLARIFIED QUESTION: Does FDA require laboratories to verify and validate tests that have not been reviewed prior to use?
CLARIFIED ANSWER: FDA requires laboratories to verify and validate tests that were not reviewed to ensure accuracy before use.
VERBATIM QUESTION: Does FDA require laboratories to verify and validate tests that have not been reviewed prior to use?
VERBATIM ANSWER: That was an important element of the prior policy to ensure that, to some degree, these tests that were not previously reviewed were performed in an excellent manner and also that the laboratory did perform their verification and their validation of those tests to ensure accuracy prior to putting them into service.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: laboratory test validation, FDA testing policy
REVIEW FLAG: False

QA Block 3-9
CLARIFIED QUESTION: Does CMS allow rapid certification of new CLIA-waived sites in the US?
CLARIFIED ANSWER: CMS is responsible for certifying CLIA-waived sites and appears to be proactive in helping providers obtain new certificates.
VERBATIM QUESTION: Does CMS allow rapid certification of new CLIA-waived sites in the US?
VERBATIM ANSWER: There are actually, to my understanding, quite a few CLIA-waived sites in the US and I believe, and I would confirm with CMS, that they're very open for business and will work a provider to generate new certificates as may be FDA Townhall needed. And I guess, you know, it's not really a question that I can answer because that's not in our regulatory purview but it's in CMS's.
SPEAKER QUESTION: Tim Salter
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CLIA-waived site certification, CMS role
REVIEW FLAG: False

QA Block 3-10
CLARIFIED QUESTION: What is the FDA's role in determining whether a test can be a waived test or a deemed waived test?
CLARIFIED ANSWER: FDA evaluates whether a test can be performed outside of high- or moderately-complex labs and determines if it can be classified as a waived or deemed waived test.
VERBATIM QUESTION: What is the FDA's role in determining whether a test can be a waived test or a deemed waived test?
VERBATIM ANSWER: We assess whether or not a test can be accurately performed outside of a high-complexity or moderately complex lab and then make the assessment about whether it can be a waived type test or a deemed waive test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Test waiver assessment, FDA's regulatory role
REVIEW FLAG: False


#### 4. Clarifying Pre-EUA Pathways and Testing Guidance Updates

QA Block 4-1
CLARIFIED QUESTION: What is the relationship of the umbrella pathway to the guidance issued on May 4?
CLARIFIED ANSWER: The umbrella pathway is a streamlined process designed to support developers using serum and plasma tests. It allows NCI testing for EUA authorization but is limited in scope and does not cover near-patient, lay-user, or home testing.
VERBATIM QUESTION: What is the relationship of the umbrella pathway to the guidance issued on May 4?
VERBATIM ANSWER: Now you also asked about what the difference is between the umbrella and this new guidance on Monday this week. So the umbrella was designed for companies that wanted to basically utilize the NCI testing for supporting their EUA authorization. Now since - at NCI we're at the moment limiting testing to serum and plasma, the sample types that are allowed under that umbrella are limited to serum and plasma, and there are many developers who wish to have more than that and so they may wan whole blood, they may want finger stick. The other thing we couldn't assess under that regulatory pathway, the umbrella pathway was saying near-patient testing, lay-user testing and certainly not home testing or home collection. So the umbrella is really kind of a streamlined pathway for those developers that have a serum and plasma tests and the testing - and the testing of the device could be essentially composing at NCI without any additional testing for those narrow uses.
SPEAKER QUESTION: Brandt Mitler
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: umbrella pathway, May 4 guidance, NCI testing limitations
REVIEW FLAG: False

QA Block 4-2
CLARIFIED QUESTION: Can a manufacturer send 125 test kits to the NCI to jumpstart the voluntary testing program while also working on either a pre-EUA or EUA?
CLARIFIED ANSWER: Yes, a manufacturer can send 125 test kits to the NCI while working on a pre-EUA or EUA, but the FDA will assess whether NCI testing is warranted based on prior validation.
VERBATIM QUESTION: Can a manufacturer send 125 test kits to the NCI to jumpstart the voluntary testing program while also working on either a pre-EUA or EUA?
VERBATIM ANSWER: As far as NCI, yes. You can reach out to the templates email address CDRH- EUA-Templates@fda.hhs.gov and request the opportunity to send your test to the NCI and we would probably do an assessment now because there's been quite a strong interest and, you know, we would assess whether or not NCI testing is warranted or not, depending on what validation you may have already performed.
SPEAKER QUESTION: Brandt Mitler
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: NCI voluntary testing program, pre-EUA/EUA process, FDA assessment
REVIEW FLAG: False

QA Block 4-3
CLARIFIED QUESTION: Does the pre-EUA pathway still exist?
CLARIFIED ANSWER: Yes, the pre-EUA pathway still exists, offering an opportunity for developers to consult with the FDA. It is less critical now due to the availability of finalized templates, though it remains relevant for special cases like novel sample types.
VERBATIM QUESTION: Does the pre-EUA pathway still exist?
VERBATIM ANSWER: Yes. A pre-EUA is basically an opportunity to come in and ask questions. It might be, you know, is this an adequate way to validate a test or, you know, for a CLIA-waived test, something like that. Now that we have - the pre-EUA pathway though was a little bit more important when the templates weren't yet finalized and made available. Now that they're finalized and made available, we hope that there's enough information there for all the common variety uses. There will still be some special cases. We - for example, saliva could actually be a sample type for not just molecular but serological tests and even direct antigen tests. So we still view that sample type as something that we want to carefully look at and would engage. But it's our hope that going forward if there's a possibility, say, that saliva might be used, that we'll provide some recommendations in the template for saliva.
SPEAKER QUESTION: Brandt Mitler
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-EUA pathway, FDA templates, special cases like saliva
REVIEW FLAG: False

QA Block 4-4
CLARIFIED QUESTION: How should saliva samples be validated for serological or direct antigen tests?
CLARIFIED ANSWER: Saliva can be used for serological and direct antigen tests, and the FDA will carefully assess its validation. Recommendations for saliva validation are included in the templates, which FDA encourages manufacturers to use.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: We - for example, saliva could actually be a sample type for not just molecular but serological tests and even direct antigen tests. So we still view that sample type as something that we want to carefully look at and would engage. But it's our hope that going forward if there's a possibility, say, that saliva might be used, that we'll provide some recommendations in the template for saliva. So I would encourage folks to utilize the information in the templates as much as possible.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Saliva sample validation, Serological tests, Templates
REVIEW FLAG: False

QA Block 4-5
CLARIFIED QUESTION: Are templates available with specific recommendations for validating saliva as a sample type?
CLARIFIED ANSWER: FDA templates now include recommendations for saliva as a sample type for various tests. Saliva is treated as a special case, but the FDA encourages utilizing the provided template guidance.
VERBATIM QUESTION: Are templates available with specific recommendations for validating saliva as a sample type?
VERBATIM ANSWER: Now that they're finalized and made available, we hope that there's enough information there for all the common variety uses. There will still be some special cases. We - for example, saliva could actually be a sample type for not just molecular but serological tests and even direct antigen tests. So we still view that sample type as something that we want to carefully look at and would engage. But it's our hope that going forward if there's a possibility, say, that saliva might be used, that we'll provide some recommendations in the template for saliva. So I would encourage folks to utilize the information in the templates as much as possible.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: saliva sample validation, FDA templates, test recommendations
REVIEW FLAG: False

QA Block 4-6
CLARIFIED QUESTION: What validation steps might make the use of NCI resources unnecessary or less critical?
CLARIFIED ANSWER: The FDA hopes the finalized templates provide sufficient guidance to cover common validation needs, reducing reliance on discussions or NCI resources. Developers should use updated templates as much as possible.
VERBATIM QUESTION: What validation steps might make the use of NCI resources unnecessary or less critical?
VERBATIM ANSWER: Now that we have - the pre-EUA pathway though was a little bit more important when the templates weren't yet finalized and made available. Now that they're finalized and made available, we hope that there's enough information there for all the common variety uses. There will still be some special cases. We - for example, saliva could actually be a sample type for not just molecular but serological tests and even direct antigen tests. So we still view that sample type as something that we want to carefully look at and would engage. But it's our hope that going forward if there's a possibility, say, that saliva might be used, that we'll provide some recommendations in the template for saliva. So I would encourage folks to utilize the information in the templates as much as possible. Our team is very, very busy so we're there to help out as needed but hopefully by providing this additional information in the form of templates, the need for a new requirement or, you know, the importance of, you know, going and discussing your device and your study with the FDA may be minimized.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: NCI resources, Validation steps, Templates usage
REVIEW FLAG: False

QA Block 4-7
CLARIFIED QUESTION: What criteria does the FDA use to decide if NCI testing is warranted?
CLARIFIED ANSWER: FDA evaluates whether NCI testing is warranted based on the validation already performed and aims to use NCI resources strategically.
VERBATIM QUESTION: What criteria does the FDA use to decide if NCI testing is warranted?
VERBATIM ANSWER: You can reach out to the templates email address CDRH- EUA-Templates@fda.hhs.gov and request the opportunity to send your test to the NCI and we would probably do an assessment now because there's been quite a strong interest and, you know, we would assess whether or not NCI testing is warranted or not, depending on what validation you may have already performed. FDA Townhall And so we may be a little bit more strategic in the use of NCI resources and how we go forward with that.
SPEAKER QUESTION: Brandt Mitler
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: NCI testing criteria, FDA validation assessment
REVIEW FLAG: False

QA Block 4-8
CLARIFIED QUESTION: What are the limitations of the umbrella pathway concerning sample types like whole blood or finger-stick?
CLARIFIED ANSWER: The umbrella pathway is currently limited to serum and plasma samples. It does not accommodate whole blood, finger-stick samples, near-patient testing, lay-user testing, or home testing/collection.
VERBATIM QUESTION: What are the limitations of the umbrella pathway concerning sample types like whole blood or finger-stick?
VERBATIM ANSWER: Now since - at NCI we're at the moment limiting testing to serum and plasma, the sample types that are allowed under that umbrella are limited to serum and plasma, and there are many developers who wish to have more than that and so they may wan whole blood, they may want finger stick. The other thing we couldn't assess under that regulatory pathway, the umbrella pathway was saying near-patient testing, lay-user testing and certainly not home testing or home collection.
SPEAKER QUESTION: Brandt Mitler
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Umbrella pathway limitations, Sample types, Regulatory guidance
REVIEW FLAG: False

QA Block 4-9
CLARIFIED QUESTION: Can the umbrella pathway be used for tests designed for home testing or home collection?
CLARIFIED ANSWER: The umbrella pathway cannot be used for home testing or home collection. It is streamlined for serum and plasma-based tests evaluated under narrow uses.
VERBATIM QUESTION: Can the umbrella pathway be used for tests designed for home testing or home collection?
VERBATIM ANSWER: The other thing we couldn't assess under that regulatory pathway, the umbrella pathway was saying near-patient testing, lay-user testing and certainly not home testing or home collection. So the umbrella is really kind of a streamlined pathway for those developers that have a serum and plasma tests and the testing - and the testing of the device could be essentially composing at NCI without any additional testing for those narrow uses.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: umbrella pathway, home testing, test collection
REVIEW FLAG: False

QA Block 4-10
CLARIFIED QUESTION: What additional studies are recommended for tests outside the narrow uses supported by the umbrella pathway?
CLARIFIED ANSWER: Additional studies beyond the umbrella pathway may be needed for tests using whole blood, finger stick, near-patient testing, lay-user testing, or home testing and home collection.
VERBATIM QUESTION: What additional studies are recommended for tests outside the narrow uses supported by the umbrella pathway?
VERBATIM ANSWER: Now since - at NCI we're at the moment limiting testing to serum and plasma, the sample types that are allowed under that umbrella are limited to serum and plasma, and there are many developers who wish to have more than that and so they may wan whole blood, they may want finger stick. The other thing we couldn't assess under that regulatory pathway, the umbrella pathway was saying near-patient testing, lay-user testing and certainly not home testing or home collection.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: umbrella pathway, additional studies, testing limitations
REVIEW FLAG: False


#### 5. Managing EUA Submissions with NCI Testing Pathway Guidance

QA Block 5-1
CLARIFIED QUESTION: How should manufacturers manage results from testing with NCI while meeting the requirement to submit an EUA by May 18?
CLARIFIED ANSWER: Manufacturers must submit an EUA application regardless of whether they use the NCI testing pathway. If relying solely on NCI data, FDA will work with developers to align on the testing. Developers can email the templates address for updates. They can notify FDA and have 10 days to submit the EUA, allowing the test to remain on the market during review.
VERBATIM QUESTION: How should manufacturers manage results from testing with NCI while meeting the requirement to submit an EUA by May 18?
VERBATIM ANSWER: Yeah, so the requirement to submit an EUA e exists whether or not you've utilized the NCI testing pathway. Simply notifying us and saying that it was never really an option, well I'm going to submit it to the NCI and that's going to be my validation, so that's not a notified pathway. If you are intent on using just the NCI data, then we would want to work with you or any such developers to just be along the testing. Again an email to the template's address if you haven't been assigned a primary reviewer, we can give you an update on the status. But we do intend to, where for those folks that either submit tests to the NCI or we have a request that they submit their test to the NCI, we will use that information in our decision making. Also I'd say that the guidance on Monday didn't change the fact that test developers can still notify us as long as they file within 10 days a EUA and they can markets and stay on the market while we do our review.
SPEAKER QUESTION: Sue Warner
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: NCI testing pathway, EUA submission, FDA guidance
REVIEW FLAG: False

QA Block 5-2
CLARIFIED QUESTION: What is the process for FDA to use NCI data in the EUA decision-making?
CLARIFIED ANSWER: FDA will use NCI data for EUA decision-making, but developers should coordinate with the FDA during testing. An email to the template address may help provide updates on status.
VERBATIM QUESTION: What is the process for FDA to use NCI data in the EUA decision-making?
VERBATIM ANSWER: If you are intent on using just the NCI data, then we would want to work with you or any such developers to just be along the testing. Again an email to the template's address if you haven't been assigned a primary reviewer, we can give you an update on the status. But we do intend to, where for those folks that either submit tests to the NCI or we have a request that they submit their test to the NCI, we will use that information in our decision making.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: NCI data usage, EUA process, FDA coordination
REVIEW FLAG: False

QA Block 5-3
CLARIFIED QUESTION: If a primary reviewer has not been assigned, how should developers contact the FDA for updates on their test submissions?
CLARIFIED ANSWER: Developers should email the FDA template's address to get updates on their test submission status if a primary reviewer has not been assigned.
VERBATIM QUESTION: If a primary reviewer has not been assigned, how should developers contact the FDA for updates on their test submissions?
VERBATIM ANSWER: An email to the template's address if you haven't been assigned a primary reviewer, we can give you an update on the status.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA updates, test submission status, contact process
REVIEW FLAG: False

QA Block 5-4
CLARIFIED QUESTION: Does the updated guidance issued on Monday affect the ability of test developers to notify the FDA and market their tests while awaiting EUA approval?
CLARIFIED ANSWER: The updated FDA guidance on Monday does not affect the ability of test developers to notify the FDA and market their tests while awaiting EUA approval, provided they file for an EUA within 10 days.
VERBATIM QUESTION: Does the updated guidance issued on Monday affect the ability of test developers to notify the FDA and market their tests while awaiting EUA approval?
VERBATIM ANSWER: Also I'd say that the guidance on Monday didn't change the fact that test developers can still notify us as long as they file within 10 days a EUA and they can markets and stay on the market while we do our review.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: updated guidance, test developer notification, EUA filing process
REVIEW FLAG: False

QA Block 5-5
CLARIFIED QUESTION: Can developers market their tests during the FDA review process if they submit an EUA application within the 10-day notification period?
CLARIFIED ANSWER: Test developers can market and stay on the market during the FDA review process if they notify the FDA and submit an EUA application within the 10-day notification period.
VERBATIM QUESTION: Can developers market their tests during the FDA review process if they submit an EUA application within the 10-day notification period?
VERBATIM ANSWER: Also I'd say that the guidance on Monday didn't change the fact that test developers can still notify us as long as they file within 10 days a EUA and they can markets and stay on the market while we do our review.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submission, market approval, 10-day notification rule
REVIEW FLAG: False


#### 6. High-Quality Sample Characterization for Umbrella Pathway Developers

QA Block 6-1
CLARIFIED QUESTION: If a developer is considering the umbrella pathway, could FDA Townhall provide characterization data for the NIH stamp holder being used to help developers understand the level of characterization of the samples?
CLARIFIED ANSWER: Developers can contact the FDA's templates email for specific answers. The inter-agency group ensures high-quality, well-characterized samples, confirmed via multiple reference methods for IgM/IgG testing and historical pathogen exposure data. This may make the pathway easier for developers.
VERBATIM QUESTION: If a developer is considering the umbrella pathway, could FDA Townhall provide characterization data for the NIH stamp holder being used to help developers understand the level of characterization of the samples?
VERBATIM ANSWER: Yeah. You can address that question to get specific answers at our templates email address. But the inter-agency group is really focused on pulling together high quality samples for which we have well documented understanding of those samples. With the positive samples, we typically use two separate reference methods to establish the presence or absence of IgM or IgG. And then the negative samples are typically pre-COVID-19 and to the extent that we can utilize specific, known histories of exposure to other pathogens that we incorporate that as needed. Also as we move from say one bench of samples to another, we are trying to harmonize those efforts, but since we so carefully characterized these samples, and they are known to be either IgM or IgG positive, and it requires multiple tests in most cases to verify that a sample is negative or positive, that this really represents a situation that maybe a little bit easier for some developers because these samples are so well characterized. So we don't that this puts any developers at a disadvantage, we're open to hearing if anybody thinks that would. And so therefore I think we can expect very high performance of counts that go through that pathway.
SPEAKER QUESTION: Daniel Simpson
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: umbrella pathway, NIH stamp holder characterization, sample quality
REVIEW FLAG: False

QA Block 6-2
CLARIFIED QUESTION: What reference methods are used by the inter-agency group to confirm the presence or absence of IgM or IgG in samples?
CLARIFIED ANSWER: The inter-agency group typically uses two separate reference methods to confirm the presence or absence of IgM or IgG in positive samples. Negative samples are usually pre-COVID-19, with known exposure histories considered when possible.
VERBATIM QUESTION: What reference methods are used by the inter-agency group to confirm the presence or absence of IgM or IgG in samples?
VERBATIM ANSWER: With the positive samples, we typically use two separate reference methods to establish the presence or absence of IgM or IgG. And then the negative samples are typically pre-COVID-19 and to the extent that we can utilize specific, known histories of exposure to other pathogens that we incorporate that as needed.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: reference methods, IgM/IgG confirmation, sample characterization
REVIEW FLAG: False

QA Block 6-3
CLARIFIED QUESTION: Are negative samples used in FDA characterization pre-COVID-19, and how is their history of exposure to other pathogens documented?
CLARIFIED ANSWER: Negative samples are generally pre-COVID-19, and their known histories of exposure to other pathogens are documented and incorporated when needed.
VERBATIM QUESTION: Are negative samples used in FDA characterization pre-COVID-19, and how is their history of exposure to other pathogens documented?
VERBATIM ANSWER: The negative samples are typically pre-COVID-19 and to the extent that we can utilize specific, known histories of exposure to other pathogens that we incorporate that as needed.
SPEAKER QUESTION: Daniel Simpson
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: negative samples, exposure documentation, sample characterization
REVIEW FLAG: False

QA Block 6-4
CLARIFIED QUESTION: How does the FDA maintain consistency (harmonization) when transitioning from one batch of samples to another in the umbrella pathway?
CLARIFIED ANSWER: The FDA harmonizes efforts when transitioning samples by carefully characterizing them using multiple tests to confirm IgM or IgG positivity or negativity. This thorough characterization helps ensure high-quality samples and facilitates the process for developers.
VERBATIM QUESTION: How does the FDA maintain consistency (harmonization) when transitioning from one batch of samples to another in the umbrella pathway?
VERBATIM ANSWER: Also as we move from say one bench of samples to another, we are trying to harmonize those efforts, but since we so carefully characterized these samples, and they are known to be either IgM or IgG positive, and it requires multiple tests in most cases to verify that a sample is negative or positive, that this really represents a situation that maybe a little bit easier for some developers because these samples are so well characterized.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: sample harmonization, umbrella pathway, IgM/IgG characterization
REVIEW FLAG: False

QA Block 6-5
CLARIFIED QUESTION: Does the rigorous characterization of positive and negative samples simplify the validation process for developers using the umbrella pathway?
CLARIFIED ANSWER: The FDA confirmed that the rigorous characterization of samples could simplify the validation process for developers using the umbrella pathway, as the samples are well-documented and thoroughly tested to ensure quality.
VERBATIM QUESTION: Does the rigorous characterization of positive and negative samples simplify the validation process for developers using the umbrella pathway?
VERBATIM ANSWER: Since we so carefully characterized these samples, and they are known to be either IgM or IgG positive, and it requires multiple tests in most cases to verify that a sample is negative or positive, that this really represents a situation that maybe a little bit easier for some developers because these samples are so well characterized. So we don't that this puts any developers at a disadvantage, we're open to hearing if anybody thinks that would. And so therefore I think we can expect very high performance of counts that go through that pathway.
SPEAKER QUESTION: Daniel Simpson
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: validation process, sample characterization, umbrella pathway
REVIEW FLAG: False

QA Block 6-6
CLARIFIED QUESTION: Does the FDA believe that characterized samples under the umbrella pathway ensure high performance for diagnostic counts?
CLARIFIED ANSWER: The FDA believes the well-characterized samples under the umbrella pathway ensure high performance for diagnostic counts due to stringent testing and documentation, though they are open to feedback from developers.
VERBATIM QUESTION: Does the FDA believe that characterized samples under the umbrella pathway ensure high performance for diagnostic counts?
VERBATIM ANSWER: But the inter-agency group is really focused on pulling together high quality samples for which we have well documented understanding of those samples. With the positive samples, we typically use two separate reference methods to establish the presence or absence of IgM or IgG. And then the negative samples are typically pre-COVID-19 and to the extent that we can utilize specific, known histories of exposure to other pathogens that we incorporate that as needed. Also as we move from say one bench of samples to another, we are trying to harmonize those efforts, but since we so carefully characterized these samples, and they are known to be either IgM or IgG positive, and it requires multiple tests in most cases to verify that a sample is negative or positive, that this really represents a situation that maybe a little bit easier for some developers because these samples are so well characterized. So we don't that this puts any developers at a disadvantage, we're open to hearing if anybody thinks that would. And so therefore I think we can expect very high performance of counts that go through that pathway.
SPEAKER QUESTION: Daniel Simpson
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: umbrella pathway, sample characterization, diagnostic performance
REVIEW FLAG: False

QA Block 6-7
CLARIFIED QUESTION: What feedback mechanism exists for developers if they perceive the sample characterization in the umbrella pathway as a disadvantage?
CLARIFIED ANSWER: The FDA is open to feedback from developers if they feel the sample characterization in the umbrella pathway presents a disadvantage.
VERBATIM QUESTION: What feedback mechanism exists for developers if they perceive the sample characterization in the umbrella pathway as a disadvantage?
VERBATIM ANSWER: So we don't that this puts any developers at a disadvantage, we're open to hearing if anybody thinks that would.
SPEAKER QUESTION: Daniel Simpson
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: umbrella pathway, developer feedback, sample characterization
REVIEW FLAG: False


#### 7. Guidance for Manufacturers Submitting Tests for NCI Evaluation

QA Block 7-1
CLARIFIED QUESTION: How many test kits would be required for submission to the NCI for evaluation, such as for the "You're Immune" test?
CLARIFIED ANSWER: The FDA advises contacting their templates email address for guidance on the number of test kits required, as this depends on the technology and specific device requirements.
VERBATIM QUESTION: How many test kits would be required for submission to the NCI for evaluation, such as for the "You're Immune" test?
VERBATIM ANSWER: And then as far as the number goes, that's a great question to send to our templates address. Those that aren't lateral flow devices, we do want to make an assessment to make sure that we have the capability of performing the testing for those particular devices. You know, do we have the correct instrumentation et cetera? And as far as the number of tests for that situation, I'm unfortunately not the one to ask, but you're correct, some of them are not lateral flow, and the actual requirements for us would depend on the technology. Yeah, that's a great question for the templates email address CDRH-EUA-Templates@fda.hhs.gov.
SPEAKER QUESTION: Jason Robotham
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Number of test kits for NCI evaluation, FDA EUA applications
REVIEW FLAG: False

QA Block 7-2
CLARIFIED QUESTION: Should manufacturers going through NCI validation still submit an EUA application at the same time or wait for the umbrella pathway?
CLARIFIED ANSWER: Manufacturers with their own validation data should submit an EUA application simultaneously while noting their intent to send tests to the NCI for evaluation.
VERBATIM QUESTION: Should manufacturers going through NCI validation still submit an EUA application at the same time or wait for the umbrella pathway?
VERBATIM ANSWER: If they have their own data to support their validation, I would recommend getting the EUA application going. And you can note in that application that you've requested to send tests to the NCI for inclusion in the evaluation of your test.
SPEAKER QUESTION: Jason Robotham
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submission, NCI validation, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 7-3
CLARIFIED QUESTION: What information should be included in an EUA application if the test manufacturer is also submitting tests for NCI evaluation?
CLARIFIED ANSWER: FDA recommends submitting an EUA application if the manufacturer has their own validation data and specifying in the application that the test has been sent to NCI for evaluation.
VERBATIM QUESTION: What information should be included in an EUA application if the test manufacturer is also submitting tests for NCI evaluation?
VERBATIM ANSWER: If they have their own data to support their validation, I would recommend getting the EUA application going. And you can note in that application that you've requested to send tests to the NCI for inclusion in the evaluation of your test.
SPEAKER QUESTION: Jason Robotham
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA application requirements, NCI evaluation submission
REVIEW FLAG: False

QA Block 7-4
CLARIFIED QUESTION: How does the FDA determine capability and instrumentation needs for testing non-lateral flow devices as part of the NCI evaluation?
CLARIFIED ANSWER: The FDA assesses whether it has the needed capability and correct instrumentation for testing non-lateral flow devices.
VERBATIM QUESTION: How does the FDA determine capability and instrumentation needs for testing non-lateral flow devices as part of the NCI evaluation?
VERBATIM ANSWER: Those that aren't lateral flow devices, we do want to make an assessment to make sure that we have the capability of performing the testing for those particular devices. You know, do we have the correct instrumentation et cetera?
SPEAKER QUESTION: Jason Robotham
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: NCI evaluation, non-lateral flow devices, instrumentation needs
REVIEW FLAG: False

QA Block 7-5
CLARIFIED QUESTION: What are the requirements for submitting test kits to the FDA that do not fall under the lateral flow category?
CLARIFIED ANSWER: For non-lateral-flow test kits, the FDA assesses the capability of performing validation testing, considering factors like instrumentation. Specific requirements depend on the technology, and further inquiries can be directed to CDRH-EUA-Templates@fda.hhs.gov.
VERBATIM QUESTION: What are the requirements for submitting test kits to the FDA that do not fall under the lateral flow category?
VERBATIM ANSWER: Those that aren't lateral flow devices, we do want to make an assessment to make sure that we have the capability of performing the testing for those particular devices. You know, do we have the correct instrumentation et cetera? And as far as the number of tests for that situation, I'm unfortunately not the one to ask, but you're correct, some of them are not lateral flow, and the actual requirements for us would depend on the technology. Yeah, that's a great question for the templates email address CDRH-EUA-Templates@fda.hhs.gov.
SPEAKER QUESTION: Jason Robotham
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Non-lateral-flow test kit requirements, FDA submission process
REVIEW FLAG: False


#### 8. EUA Test Settings and Authorization Limitations Clarified

QA Block 8-1
CLARIFIED QUESTION: What are the authorized settings for use of serology lateral flow tests that do not have an EUA?
CLARIFIED ANSWER: Until an EUA is issued, serology lateral flow tests can only be used in highly complex laboratories.
VERBATIM QUESTION: What are the authorized settings for use of serology lateral flow tests that do not have an EUA?
VERBATIM ANSWER: Under Section D in your new guidance, it indicates that unless and until an EUA is issued, the authorized additional testing environments is limited to highly complex laboratories. So that means that they could only be used in highly complex laboratories until the EUA has been issued and then further designated.
SPEAKER QUESTION: Wes Wilson
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: authorized testing environments, serology tests without EUA, EUA process
REVIEW FLAG: False

QA Block 8-2
CLARIFIED QUESTION: Why isn't it more clear in FDA guidance that only highly complex laboratories can run certain tests without an EUA?
CLARIFIED ANSWER: The FDA clarified that it has attempted to be clear in its guidance and FAQs about test complexity categorizations and limitations of the notification pathway. Tests not authorized through EUA are restricted to highly complex laboratories, and tests designed for moderately complex or waived environments cannot be classified as such until reviewed and authorized.
VERBATIM QUESTION: Why isn't it more clear in FDA guidance that only highly complex laboratories can run certain tests without an EUA?
VERBATIM ANSWER: So we've attempted to be clear in our FAQ page as it regards to the list of notified users and if they have not yet notified developers, rather in Section D. And we attempted to make this very clear in terms of what hasn't been authorized, the complexity categorization, and eventually hopefully point of care waived testing. We do show the designation, even for those tests that have not been authorized so in order to classify a test as moderately complex or waived in current in what you see, it is required that we actually make an authorization decision before we can do something to be suitable for moderately complex or waived. And so that's unfortunately the limitation of the notification pathway, that even though a test may be designed for a moderately complex lab, and/or a waived environment, we cannot deem it as such until we have reviewed it and made an authorization decision.
SPEAKER QUESTION: Wes Wilson
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA limitations, Test complexity, Highly complex laboratories
REVIEW FLAG: False

QA Block 8-3
CLARIFIED QUESTION: Can serology lateral flow tests only be used in highly complex laboratories until an EUA is issued and a complexity designation is made?
CLARIFIED ANSWER: Serology lateral flow tests can only be used in highly complex laboratories until an EUA is issued and a complexity designation is made, although highly complex labs may perform point-of-care tests as long as they hold the necessary certifications.
VERBATIM QUESTION: Can serology lateral flow tests only be used in highly complex laboratories until an EUA is issued and a complexity designation is made?
VERBATIM ANSWER: That is correct. Although there are potentially highly complexity labs that have an opportunity to do point of care type tests.
SPEAKER QUESTION: Wes Wilson
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA for serology tests, Laboratory complexity requirements, Point-of-care testing
REVIEW FLAG: False

QA Block 8-4
CLARIFIED QUESTION: Are highly complex facilities able to perform point of care testing under their certification?
CLARIFIED ANSWER: Highly complex facilities can perform point of care testing, provided they hold a valid highly complex laboratory certification.
VERBATIM QUESTION: Are highly complex facilities able to perform point of care testing under their certification?
VERBATIM ANSWER: It doesn't preclude them for using it in a more flexible manner as long as they carry a highly complex certificate.
SPEAKER QUESTION: Wes Wilson
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Point of care testing, Highly complex lab certification, EUA requirements
REVIEW FLAG: False


#### 9. FDA Approaches to COVID-19 Testing Flexibility

QA Block 9-1
CLARIFIED QUESTION: Is FDA considering deferring to states on the issue of access to COVID-19 testing instead of maintaining the RX-only requirement?
CLARIFIED ANSWER: FDA currently requires physicians or clinicians with prescribing capabilities to be involved in testing but is open to exploring alternative models and will further investigate this issue.
VERBATIM QUESTION: Is FDA considering deferring to states on the issue of access to COVID-19 testing instead of maintaining the RX-only requirement?
VERBATIM ANSWER: To answer I want to make sure that I have it. So today we have operated under the expectation that physicians or clinicians with prescribing capability would be involved in the testing to ensure that the results are accurately relayed back to the patient and the healthcare team that is making decisions. We are open to other models and if you have a way of wanting to do that come and chat with us. I have made a note about what we can do potentially proactively with this. I know that - and I don't want to speak out of turn - that this question has come up, I just don't know if some federal entity has made any pronouncements about that, it wouldn't have come from the office that I direct. And I'm not sure where it would come from. It may be - I'm not even going to speculate, but I will take that back and hopefully provide a way to make that more clear.
SPEAKER QUESTION: Chris Kepi
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: RX-only requirement, state controls on test orders, FDA authorization models
REVIEW FLAG: False

QA Block 9-2
CLARIFIED QUESTION: Does FDA have specific tenets or guidance regarding authorization of COVID-19 testing for non-prescription use?
CLARIFIED ANSWER: The FDA currently expects that physicians or clinicians with prescribing capabilities oversee testing to ensure accurate communication of results. However, the FDA is open to alternative models and will consider feedback to clarify or adapt approaches.
VERBATIM QUESTION: Does FDA have specific tenets or guidance regarding authorization of COVID-19 testing for non-prescription use?
VERBATIM ANSWER: So today we have operated under the expectation that physicians or clinicians with prescribing capability would be involved in the testing to ensure that the results are accurately relayed back to the patient and the healthcare team that is making decisions. We are open to other models and if you have a way of wanting to do that come and chat with us. I have made a note about what we can do potentially proactively with this. I know that - and I don't want to speak out of turn - that this question has come up, I just don't know if some federal entity has made any pronouncements about that, it wouldn't have come from the office that I direct. And I'm not sure where it would come from. It may be - I'm not even going to speculate, but I will take that back and hopefully provide a way to make that more clear.
SPEAKER QUESTION: Chris Kepi
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Non-prescription testing, Authorization guidelines, Healthcare provider role
REVIEW FLAG: False

QA Block 9-3
CLARIFIED QUESTION: Is FDA expecting to see differences among different types of asymptomatic patients in terms of test performance?
CLARIFIED ANSWER: FDA is open to claims for asymptomatic testing but requires data on test performance in such populations. Current testing discretion lies with healthcare providers, and further data is needed to support performance claims for asymptomatic carriers specifically.
VERBATIM QUESTION: Is FDA expecting to see differences among different types of asymptomatic patients in terms of test performance?
VERBATIM ANSWER: It really has to do with, from an FDA perspective, about whether or not evidence is provided that would allow use, or claim use, in asymptomatic populations. I would say I've seen various reports that maybe 20% of SARS coronavirus 2 patients are asymptomatic or maybe presymptomatic and then, of course, there's maybe time periods after symptoms has resolved if they've had SARS coronavirus 2 at which point, for some period of time, they may still be shedding virus. Whether that virus has the ability to infect others or not, may not be known at the present time. So we have typically said that these diagnostic tests, which are not serology tests but rather molecular tests and potentially feature rapid antigen tests that these are intended for populations that are suspected of having COVID-19. Primarily because we have a better understanding of those populations. As our knowledge grows about asymptomatic patients, and what methods may be able to be used to detect whether somebody is an asymptomatic carrier or shatter, and what sample type is best, what swab type might be best, maybe there are multiple sites, maybe there are multiple swab types that would be useful. But for the time being and how evidence is presented in some way to the FDA, we are very open to claims around asymptomatic testing. But for now, our statement is on our website now that testing of asymptomatic individuals who are suspected of COVID-19 is at the discretion of the health care provider. And so that can be somebody, you know, it's up to the healthcare prescriber and so we have offered from at least in FDA perspective, maximal flexibility for use of that. And again, we are very willing to authorize a test for use in asymptomatic individuals. We just, we would like to see the data that supports that, you know, what the performance in such a population would be. For example, what percentage of asymptomatic carriers would be - would test positive. Is there any risk of false positives? So those are not necessarily easy studies to carry out. And designing them to assess whether or not somebody is an asymptomatic carrier, you know, would require some discussion with our FDA Townhall team.
SPEAKER QUESTION: Chris Kepi
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: asymptomatic testing, test performance, evidence requirements
REVIEW FLAG: False

QA Block 9-4
CLARIFIED QUESTION: What is driving the need for further validation to support general crowd testing?
CLARIFIED ANSWER: FDA requires evidence on performance in asymptomatic populations and considers challenges like testing accuracy and false positives for general crowd testing validation.
VERBATIM QUESTION: What is driving the need for further validation to support general crowd testing?
VERBATIM ANSWER: It really has to do with, from an FDA perspective, about whether or not evidence is provided that would allow use, or claim use, in asymptomatic populations. I would say I've seen various reports that maybe 20% of SARS coronavirus 2 patients are asymptomatic or maybe presymptomatic and then, of course, there's maybe time periods after symptoms has resolved if they've had SARS coronavirus 2 at which point, for some period of time, they may still be shedding virus. Whether that virus has the ability to infect others or not, may not be known at the present time. So we have typically said that these diagnostic tests, which are not serology tests but rather molecular tests and potentially feature rapid antigen tests that these are intended for populations that are suspected of having COVID-19. Primarily because we have a better understanding of those populations. As our knowledge grows about asymptomatic patients, and what methods may be able to be used to detect whether somebody is an asymptomatic carrier or shatter, and what sample type is best, what swab type might be best, maybe there are multiple sites, maybe there are multiple swab types that would be useful. But for the time being and how evidence is presented in some way to the FDA, we are very open to claims around asymptomatic testing. But for now, our statement is on our website now that testing of asymptomatic individuals who are suspected of COVID-19 is at the discretion of the health care provider. And so that can be somebody, you know, it's up to the healthcare prescriber and so we have offered from at least in FDA perspective, maximal flexibility for use of that. And again, we are very willing to authorize a test for use in asymptomatic individuals. We just, we would like to see the data that supports that, you know, what the performance in such a population would be. For example, what percentage of asymptomatic carriers would be - would test positive. Is there any risk of false positives? So those are not necessarily easy studies to carry out. And designing them to assess whether or not somebody is an asymptomatic carrier, you know, would require some discussion with our FDA Townhall team.
SPEAKER QUESTION: Chris Kepi
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: asymptomatic testing, validation for crowd testing, evidence for FDA authorization
REVIEW FLAG: False

QA Block 9-5
CLARIFIED QUESTION: Are there any existing FDA guidelines or FAQ updates regarding new models for addressing the RX-only requirement for test ordering?
CLARIFIED ANSWER: The FDA currently expects physicians or clinicians with prescribing authority to oversee testing, ensuring accurate communication of results to patients and healthcare teams. While open to alternative models, the FDA encourages discussions on this and considers using its FAQ page to clarify updates.
VERBATIM QUESTION: Are there any existing FDA guidelines or FAQ updates regarding new models for addressing the RX-only requirement for test ordering?
VERBATIM ANSWER: To answer I want to make sure that I have it. So today we have operated under the expectation that physicians or clinicians with prescribing capability would be involved in the testing to ensure that the results are accurately relayed back to the patient and the healthcare team that is making decisions. We are open to other models and if you have a way of wanting to do that come and chat with us. I have made a note about what we can do potentially proactively with this. I know that - and I don't want to speak out of turn - that this question has come up, I just don't know if some federal entity has made any pronouncements about that, it wouldn't have come from the office that I direct. And I'm not sure where it would come from. It may be - I'm not even going to speculate, but I will take that back and hopefully provide a way to make that more clear.
SPEAKER QUESTION: Chris Kepi
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: RX-only requirement for test ordering, FDA guidelines, Alternative test ordering models
REVIEW FLAG: False

QA Block 9-6
CLARIFIED QUESTION: What kind of data would the FDA require to support claims for COVID-19 diagnostic tests specifically designed for asymptomatic populations?
CLARIFIED ANSWER: The FDA is open to claims for COVID-19 diagnostic tests for asymptomatic populations but requires evidence supporting their use. This includes performance data, such as the percentage of asymptomatic carriers testing positive and risks of false positives. These studies are complex and require discussion with the FDA.
VERBATIM QUESTION: What kind of data would the FDA require to support claims for COVID-19 diagnostic tests specifically designed for asymptomatic populations?
VERBATIM ANSWER: It really has to do with, from an FDA perspective, about whether or not evidence is provided that would allow use, or claim use, in asymptomatic populations. I would say I've seen various reports that maybe 20% of SARS coronavirus 2 patients are asymptomatic or maybe presymptomatic and then, of course, there's maybe time periods after symptoms has resolved if they've had SARS coronavirus 2 at which point, for some period of time, they may still be shedding virus. Whether that virus has the ability to infect others or not, may not be known at the present time. So we have typically said that these diagnostic tests, which are not serology tests but rather molecular tests and potentially feature rapid antigen tests that these are intended for populations that are suspected of having COVID-19. Primarily because we have a better understanding of those populations. As our knowledge grows about asymptomatic patients, and what methods may be able to be used to detect whether somebody is an asymptomatic carrier or shatter, and what sample type is best, what swab type might be best, maybe there are multiple sites, maybe there are multiple swab types that would be useful. But for the time being and how evidence is presented in some way to the FDA, we are very open to claims around asymptomatic testing. But for now, our statement is on our website now that testing of asymptomatic individuals who are suspected of COVID-19 is at the discretion of the health care provider. And so that can be somebody, you know, it's up to the healthcare prescriber and so we have offered from at least in FDA perspective, maximal flexibility for use of that. And again, we are very willing to authorize a test for use in asymptomatic individuals. We just, we would like to see the data that supports that, you know, what the performance in such a population would be. For example, what percentage of asymptomatic carriers would be - would test positive. Is there any risk of false positives? So those are not necessarily easy studies to carry out. And designing them to assess whether or not somebody is an asymptomatic carrier, you know, would require some discussion with our FDA Townhall team.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID-19 tests, Asymptomatic population, Data requirements
REVIEW FLAG: False

QA Block 9-7
CLARIFIED QUESTION: Is the FDA open to revising the definition of "suspected COVID-19" to include asymptomatic individuals within their intended use criteria without further validation?
CLARIFIED ANSWER: FDA has not revised the definition of "suspected COVID-19" to fully include asymptomatic individuals without validation but is open to reviewing claims for asymptomatic testing if supported by evidence. Use of such tests is currently at the discretion of healthcare providers.
VERBATIM QUESTION: Is the FDA open to revising the definition of "suspected COVID-19" to include asymptomatic individuals within their intended use criteria without further validation?
VERBATIM ANSWER: So we have typically said that these diagnostic tests, which are not serology tests but rather molecular tests and potentially feature rapid antigen tests that these are intended for populations that are suspected of having COVID-19. Primarily because we have a better understanding of those populations. As our knowledge grows about asymptomatic patients, and what methods may be able to be used to detect whether somebody is an asymptomatic carrier or shatter, and what sample type is best, what swab type might be best, maybe there are multiple sites, maybe there are multiple swab types that would be useful. But for the time being and how evidence is presented in some way to the FDA, we are very open to claims around asymptomatic testing. But for now, our statement is on our website now that testing of asymptomatic individuals who are suspected of COVID-19 is at the discretion of the health care provider. And so that can be somebody, you know, it's up to the healthcare prescriber and so we have offered from at least in FDA perspective, maximal flexibility for use of that. And again, we are very willing to authorize a test for use in asymptomatic individuals. We just, we would like to see the data that supports that, you know, what the performance in such a population would be.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: asymptomatic testing, definition of suspected COVID-19, test validation
REVIEW FLAG: False

QA Block 9-8
CLARIFIED QUESTION: What specific swab or sample types does the FDA currently recommend or anticipate might be suitable for asymptomatic COVID-19 testing?
CLARIFIED ANSWER: The FDA does not currently have specific recommendations for swab or sample types for asymptomatic COVID-19 testing but is open to multiple options as evidence develops.
VERBATIM QUESTION: What specific swab or sample types does the FDA currently recommend or anticipate might be suitable for asymptomatic COVID-19 testing?
VERBATIM ANSWER: As our knowledge grows about asymptomatic patients, and what methods may be able to be used to detect whether somebody is an asymptomatic carrier or shatter, and what sample type is best, what swab type might be best, maybe there are multiple sites, maybe there are multiple swab types that would be useful. But for the time being and how evidence is presented in some way to the FDA, we are very open to claims around asymptomatic testing.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: asymptomatic testing, swab or sample types, FDA flexibility
REVIEW FLAG: False

QA Block 9-9
CLARIFIED QUESTION: How does the FDA define sufficient evidence to validate a diagnostic test for asymptomatic carriers of SARS-CoV-2?
CLARIFIED ANSWER: The FDA requires evidence supporting claims for use of diagnostic tests in asymptomatic populations. This includes performance data on test positivity rates in asymptomatic carriers and potential risks like false positives. The FDA is open to authorizing tests for this use but relies on sufficient supporting data.
VERBATIM QUESTION: How does the FDA define sufficient evidence to validate a diagnostic test for asymptomatic carriers of SARS-CoV-2?
VERBATIM ANSWER: It really has to do with, from an FDA perspective, about whether or not evidence is provided that would allow use, or claim use, in asymptomatic populations. I would say I've seen various reports that maybe 20% of SARS coronavirus 2 patients are asymptomatic or maybe presymptomatic and then, of course, there's maybe time periods after symptoms has resolved if they've had SARS coronavirus 2 at which point, for some period of time, they may still be FDA Townhall shedding virus. Whether that virus has the ability to infect others or not, may not be known at the present time. So we have typically said that these diagnostic tests, which are not serology tests but rather molecular tests and potentially feature rapid antigen tests that these are intended for populations that are suspected of having COVID-19. Primarily because we have a better understanding of those populations. As our knowledge grows about asymptomatic patients, and what methods may be able to be used to detect whether somebody is an asymptomatic carrier or shatter, and what sample type is best, what swab type might be best, maybe there are multiple sites, maybe there are multiple swab types that would be useful. But for the time being and how evidence is presented in some way to the FDA, we are very open to claims around asymptomatic testing. But for now, our statement is on our website now that testing of asymptomatic individuals who are suspected of COVID-19 is at the discretion of the health care provider. And so that can be somebody, you know, it's up to the healthcare prescriber and so we have offered from at least in FDA perspective, maximal flexibility for use of that. And again, we are very willing to authorize a test for use in asymptomatic individuals. We just, we would like to see the data that supports that, you know, what the performance in such a population would be. For example, what percentage of asymptomatic carriers would be - would test positive. Is there any risk of false positives?
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation of diagnostic tests, Asymptomatic SARS-CoV-2 carriers, Evidence requirements
REVIEW FLAG: False


#### 10. Clarifying Molecular and Serology Test Targets and Components

QA Block 10-1
CLARIFIED QUESTION: Have you consolidated the type sequences that are in molecular tests?
CLARIFIED ANSWER: The FDA aims to ensure that molecular test targets and serology test antigens are evident to the public, although some sequences may be proprietary. Test developers can share this information with the community, and FDA supports transparency on gene targets or viral proteins used in diagnostics.
VERBATIM QUESTION: Have you consolidated the type sequences that are in molecular tests?
VERBATIM ANSWER: We were wanting to make sure that the deemed targets in molecular tests and now as we move forward, the antigens used for the serology tests are evident. Actual protein sequences of an antigen are the actual primers and probes used by a particular manufacturer or developer may be considered proprietary. And so while the agency may know they are restricted in what they can FDA Townhall provide, however the test developers want to provide that to the community, the FDA would not be opposed to that. But at a minimum, we want to make sure that people understand what are the gene targets for molecular unintelligible and watch protein what viral protein is used as the antigen in a serology test. And I think when we come to direct antigen test, what is the target of that test, what's the viral target, the protein target of the test that people can assess and study and do research and do comparative studies to understand relative performance, targeting different aspects of the virus.
SPEAKER QUESTION: Sean Higgins
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Molecular test targets, Serology test antigens, Proprietary diagnostic components
REVIEW FLAG: False

QA Block 10-2
CLARIFIED QUESTION: Have you consolidated the information about the protein components included in serology tests?
CLARIFIED ANSWER: FDA aims to make antigens in serology tests clear and understandable and ensures targets are known but notes that proprietary details, like specific protein sequences, may not be shared unless developers voluntarily provide them.
VERBATIM QUESTION: Have you consolidated the information about the protein components included in serology tests?
VERBATIM ANSWER: We were wanting to make sure that the deemed targets in molecular tests and now as we move forward, the antigens used for the serology tests are evident. Actual protein sequences of an antigen are the actual primers and probes used by a particular manufacturer or developer may be considered proprietary. And so while the agency may know they are restricted in what they can FDA Townhall provide, however the test developers want to provide that to the community, the FDA would not be opposed to that. But at a minimum, we want to make sure that people understand what are the gene targets for molecular unintelligible and watch protein what viral protein is used as the antigen in a serology test. And I think when we come to direct antigen test, what is the target of that test, what's the viral target, the protein target of the test that people can assess and study and do research and do comparative studies to understand relative performance, targeting different aspects of the virus.
SPEAKER QUESTION: Sean Higgins
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology test components, proprietary information, target identification
REVIEW FLAG: False

QA Block 10-3
CLARIFIED QUESTION: What are the proprietary limitations regarding sharing gene target information for molecular tests?
CLARIFIED ANSWER: FDA states that gene targets and protein components in molecular and serology tests may be proprietary to developers. While FDA is restricted in sharing such details, developers may voluntarily disclose them to the community. FDA emphasizes the importance of understanding these targets for research and comparative studies.
VERBATIM QUESTION: What are the proprietary limitations regarding sharing gene target information for molecular tests?
VERBATIM ANSWER: Actual protein sequences of an antigen are the actual primers and probes used by a particular manufacturer or developer may be considered proprietary. And so while the agency may know they are restricted in what they can FDA Townhall provide, however the test developers want to provide that to the community, the FDA would not be opposed to that. But at a minimum, we want to make sure that people understand what are the gene targets for molecular unintelligible and watch protein what viral protein is used as the antigen in a serology test.
SPEAKER QUESTION: Sean Higgins
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: proprietary gene target sharing, molecular test components, serology test proteins
REVIEW FLAG: False

QA Block 10-4
CLARIFIED QUESTION: What details about serology test antigens should be made publicly available?
CLARIFIED ANSWER: FDA aims to ensure that the viral proteins used as antigens in serology tests are publicly evident while respecting proprietary data. Minimum public details should include information about the viral protein antigen used, allowing researchers to assess and compare test performance.
VERBATIM QUESTION: What details about serology test antigens should be made publicly available?
VERBATIM ANSWER: We were wanting to make sure that the deemed targets in molecular tests and now as we move forward, the antigens used for the serology tests are evident. Actual protein sequences of an antigen are the actual primers and probes used by a particular manufacturer or developer may be considered proprietary. And so while the agency may know they are restricted in what they can FDA Townhall provide, however the test developers want to provide that to the community, the FDA would not be opposed to that. But at a minimum, we want to make sure that people understand what are the gene targets for molecular unintelligible and watch protein what viral protein is used as the antigen in a serology test. And I think when we come to direct antigen test, what is the target of that test, what's the viral target, the protein target of the test that people can assess and study and do research and do comparative studies to understand relative performance, targeting different aspects of the virus.
SPEAKER QUESTION: Sean Higgins
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology test antigens, proprietary data, public disclosure
REVIEW FLAG: False

QA Block 10-5
CLARIFIED QUESTION: What viral or protein targets should be identified for direct antigen tests to aid comparative studies and research?
CLARIFIED ANSWER: The FDA emphasizes the importance of identifying viral or protein targets for direct antigen tests, including understanding the viral target or protein target used. These targets aid in comparative studies, research, and performance assessments of various tests targeting different aspects of the virus.
VERBATIM QUESTION: What viral or protein targets should be identified for direct antigen tests to aid comparative studies and research?
VERBATIM ANSWER: We were wanting to make sure that the deemed targets in molecular tests and now as we move forward, the antigens used for the serology tests are evident. Actual protein sequences of an antigen are the actual primers and probes used by a particular manufacturer or developer may be considered proprietary. And so while the agency may know they are restricted in what they can FDA Townhall provide, however the test developers want to provide that to the community, the FDA would not be opposed to that. But at a minimum, we want to make sure that people understand what are the gene targets for molecular unintelligible and watch protein what viral protein is used as the antigen in a serology test. And I think when we come to direct antigen test, what is the target of that test, what's the viral target, the protein target of the test that people can assess and study and do research and do comparative studies to understand relative performance, targeting different aspects of the virus.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Direct antigen test targets, Comparative studies, Research on virus protein or viral targets
REVIEW FLAG: False

QA Block 10-6
CLARIFIED QUESTION: Are there any restrictions on developers sharing primers and probes with the community?
CLARIFIED ANSWER: Primers and probes used by test developers may be considered proprietary, but FDA is not opposed to developers sharing this information with the community.
VERBATIM QUESTION: Are there any restrictions on developers sharing primers and probes with the community?
VERBATIM ANSWER: Actual protein sequences of an antigen are the actual primers and probes used by a particular manufacturer or developer may be considered proprietary. And so while the agency may know they are restricted in what they can FDA Townhall provide, however the test developers want to provide that to the community, the FDA would not be opposed to that.
SPEAKER QUESTION: Sean Higgins
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: sharing primers and probes, proprietary information
REVIEW FLAG: False

QA Block 10-7
CLARIFIED QUESTION: Does the FDA have any recommendations for how test developers should make antigen information accessible?
CLARIFIED ANSWER: The FDA encourages test developers to make the targets of their tests, including gene and protein targets, accessible to the community where possible, despite certain proprietary restrictions.
VERBATIM QUESTION: Does the FDA have any recommendations for how test developers should make antigen information accessible?
VERBATIM ANSWER: We were wanting to make sure that the deemed targets in molecular tests and now as we move forward, the antigens used for the serology tests are evident. Actual protein sequences of an antigen are the actual primers and probes used by a particular manufacturer or developer may be considered proprietary. And so while the agency may know they are restricted in what they can FDA Townhall provide, however the test developers want to provide that to the community, the FDA would not be opposed to that. But at a minimum, we want to make sure that people understand what are the gene targets for molecular unintelligible and watch protein what viral protein is used as the antigen in a serology test. And I think when we come to direct antigen test, what is the target of that test, what's the viral target, the protein target of the test that people can assess and study and do research and do comparative studies to understand relative performance, targeting different aspects of the virus.
SPEAKER QUESTION: Sean Higgins
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antigen target information, Test developer guidance, Proprietary data limitations
REVIEW FLAG: False


#### 11. Understanding Serology Test Types and Antibody Claims

QA Block 11-1
CLARIFIED QUESTION: What is the difference between serology antibody tests with EUA and total antibody tests?
CLARIFIED ANSWER: FDA explained that serology tests can vary: some focus only on IgG and IgM antibodies, while others may claim to detect all isotypes as PAN antibody tests. Tests with limited isotype detection cannot claim to be PAN antibody tests. The FDA emphasizes accurate naming and representation of test capabilities.
VERBATIM QUESTION: What is the difference between serology antibody tests with EUA and total antibody tests?
VERBATIM ANSWER: Yes. So there's different flavors. So some test, let's say we are going to look at IgG and were going to look at IgM, there is other claims such as PAN anti- body. We expect a test that has been developed for PAN anti-body will be able to detect all of the isotypes. And then there are others that may only partially cover some of the isotypes, so they cannot claim PAN antibody tests. And so that's Nuance language is good pickup and we seek to have truth in advertising as it comes to a test name and a test target. Hopefully that's helpful.
SPEAKER QUESTION: Julie Leslie
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology antibody tests, EUA-approved tests, Test isotype detection
REVIEW FLAG: False

QA Block 11-3
CLARIFIED QUESTION: What are the FDA expectations for PAN antibody tests?
CLARIFIED ANSWER: The FDA expects PAN antibody tests to detect all antibody isotypes, while tests that only partially cover isotypes cannot claim to be PAN antibody tests. The naming of tests must reflect accurate claims.
VERBATIM QUESTION: What are the FDA expectations for PAN antibody tests?
VERBATIM ANSWER: We expect a test that has been developed for PAN anti-body will be able to detect all of the isotypes. And then there are others that may only partially cover some of the isotypes, so they cannot claim PAN antibody tests. And so that's Nuance language is good pickup and we seek to have truth in advertising as it comes to a test name and a test target.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: PAN antibody tests, Isotype detection, FDA test naming guidelines
REVIEW FLAG: False

QA Block 11-4
CLARIFIED QUESTION: How should developers label serology tests that detect only some isotypes?
CLARIFIED ANSWER: Tests that detect only some isotypes cannot claim to be PAN antibody tests. FDA emphasizes truthful labeling based on the test's target and capabilities.
VERBATIM QUESTION: How should developers label serology tests that detect only some isotypes?
VERBATIM ANSWER: Yes. So there's different flavors. So some test, let's say we are going to look at IgG and were going to look at IgM, there is other claims such as PAN anti-body. We expect a test that has been developed for PAN anti-body will be able to detect all of the isotypes. And then there are others that may only partially cover some of the isotypes, so they cannot claim PAN antibody tests. And so that's Nuance language is good pickup and we seek to have truth in advertising as it comes to a test name and a test target.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology test labeling, isotype detection, truthful advertising
REVIEW FLAG: False

QA Block 11-5
CLARIFIED QUESTION: What does the FDA mean by 'truth in advertising' for test names and targets?
CLARIFIED ANSWER: The FDA aims to ensure accuracy in how test names and their targets are described, focusing on clear distinctions such as whether a test can claim to detect all isotypes like PAN antibody or not.
VERBATIM QUESTION: What does the FDA mean by 'truth in advertising' for test names and targets?
VERBATIM ANSWER: And so that's Nuance language is good pickup and we seek to have truth in advertising as it comes to a test name and a test target.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: test naming accuracy, antibody test classifications
REVIEW FLAG: False


#### 12. FDA Review Progress on 3D Printed Swabs

QA Block 12-1
CLARIFIED QUESTION: What is the progress on the FDA's review of 3D printed swabs based on the information provided?
CLARIFIED ANSWER: FDA encourages sending inquiries to their COVIDManufacturing email for specific updates on 3D printed swabs and emphasizes forthcoming technical guidance, expected by next week.
VERBATIM QUESTION: What is the progress on the FDA's review of 3D printed swabs based on the information provided?
VERBATIM ANSWER: Yes, if you send  you can send an email to the COVIDManufacturing@fda.hhs.govand they should get back to you in short FDA Townhall order. We've done a really good job of managing that email address, even though we've had tens of thousands of emails. I know I've talked about 3D swabs on these calls in previous weeks, so please cc me on that inquiry Sara.Brenner@fda.hhs.gov and I will be sure to track down the specific case that you are asking about. We are looking forward to, as I said now for many weeks, providing more information on technical considerations for the community and our hope is to do that by next week.
SPEAKER QUESTION: William Shore
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: 3D printed swabs, FDA review progress, Technical guidance
REVIEW FLAG: False

QA Block 12-2
CLARIFIED QUESTION: Are there general questions about 3D swabs that can be addressed today?
CLARIFIED ANSWER: General questions about 3D swabs can be directed to the FDA's COVIDManufacturing email, as this call focuses on addressing general topics. Specific cases may require additional follow-up.
VERBATIM QUESTION: Are there general questions about 3D swabs that can be addressed today?
VERBATIM ANSWER: Yes, this may be in regards to a specific situation that the agency is reviewing. So I would just direct the question back to our COVIDManufacturing@fda.hhs.gov email address for specific feedback on anything that you may have submitted to the FDA. We are very interested in new technologies to address shortages are potential shortages. And the 3D swabs are part of that. But if there is a specific swab, specific developer of a swab or specific question about such swabs, I'm probably not going to be able to answer it on the call today. But our team can hopefully answer that question for you in short order.
SPEAKER QUESTION: William Shore
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: 3D swabs, FDA feedback process, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 12-3
CLARIFIED QUESTION: What specific technical considerations for 3D printed swabs does the FDA plan to provide to the community?
CLARIFIED ANSWER: The FDA plans to provide more information on technical considerations for 3D-printed swabs and hopes to release it by next week.
VERBATIM QUESTION: What specific technical considerations for 3D printed swabs does the FDA plan to provide to the community?
VERBATIM ANSWER: We are looking forward to, as I said now for many weeks, providing more information on technical considerations for the community and our hope is to do that by next week.
SPEAKER QUESTION: William Shore
SPEAKER ANSWER: Sara Brenner (FDA)
TOPICS: 3D printed swabs, FDA technical guidance, timeline for information release
REVIEW FLAG: False

QA Block 12-4
CLARIFIED QUESTION: What is the timeline for the release of updated technical guidelines related to 3D printed swabs?
CLARIFIED ANSWER: FDA aims to release updated technical guidelines on 3D printed swabs by next week.
VERBATIM QUESTION: What is the timeline for the release of updated technical guidelines related to 3D printed swabs?
VERBATIM ANSWER: We are looking forward to, as I said now for many weeks, providing more information on technical considerations for the community and our hope is to do that by next week.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Sara Brenner (FDA)
TOPICS: 3D printed swabs, technical guidelines, FDA timeline
REVIEW FLAG: False

QA Block 12-6
CLARIFIED QUESTION: Who should developers contact within the FDA to track the progress of their submissions on 3D printed swabs?
CLARIFIED ANSWER: Developers should contact COVIDManufacturing@fda.hhs.gov for follow-up on 3D printed swab submissions and can cc Sara.Brenner@fda.hhs.gov for case-specific concerns.
VERBATIM QUESTION: Who should developers contact within the FDA to track the progress of their submissions on 3D printed swabs?
VERBATIM ANSWER: Yes, if you send  you can send an email to the COVIDManufacturing@fda.hhs.gov and they should get back to you in short FDA Townhall order. We've done a really good job of managing that email address, even though we've had tens of thousands of emails. I know I've talked about 3D swabs on these calls in previous weeks, so please cc me on that inquiry Sara.Brenner@fda.hhs.gov and I will be sure to track down the specific case that you are asking about.
SPEAKER QUESTION: William Shore
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: 3D printed swabs, FDA submission tracking, Contact information
REVIEW FLAG: False


#### 13. Challenges and Alternatives in Expanding COVID-19 Testing Capacity

QA Block 13-1
CLARIFIED QUESTION: How can molecular testing not be used for the general population when it is used for contact tracing?
CLARIFIED ANSWER: Molecular testing for broader population use is limited by lab capacity to swiftly process results despite manufacturers' efforts. FDA and CMS have provided flexibility to expand testing capacity and are developing rapid antigen tests to ease constraints, despite challenges in sensitivity.
VERBATIM QUESTION: how can molecular testing not be used for the general population when it is used for contact tracing?
VERBATIM ANSWER: Yes. No, that's a great question and it's a challenging situation. And although we the manufacturers have really done a great job on the molecular test, at least make the PCR readings in high abundance, a lot of high throughput manufacturers have come on to the market with UA authorizations. But even so, the need for testing and the desire for the molecular testing has a tendency to potentially outstrip the lab capacity to, you know, return molecular results in a timely matter for if you really want to expand testing into more populations. So that is definitely a challenge. It's definitely one that we've been thinking about and others in the government have been thinking about how to handle. Unfortunately, CMS has provided some flexibility here. The FDA has provided some flexibility as well in that we've on our FAQ page for alternative ways to do molecular testing, we are allowing an expanding number of essay PCR instruments to be used, properly validated some sort of bridging city by the lab. And CMS has - to my understanding - given the ability to expand a CLIA lab to be able to use other instruments that may be on campus. So I will just refer you to the CMS memo. That said, we know that expanded testing is FDA Townhall really a requirement. And we are very encouraged that there are a number of developers that are developing a rapid antigen test. Now, traditionally have not been as sensitive as molecular tests, that's a known challenge. We have been reaching and discussing tests with stakeholder communities and professional organizations. And although we know that the performance may be less sensitive, say, then a molecular test, there may still be value if users understand the performance of these tests and the proper use of these tests and the proper interpretation and use of results. So for example, some of these rapid tests may be very specific so if you get a positive result in a short amount of time, you can probably act on it. If you get a negative result, you will want to understand what is the sensitivity of the test, what is the potential for a false negative, and use other information that's available to healthcare workers to assess what is the proper follow-up for the patient. Perhaps it's a reflex to a molecular test in the appropriate situations. The advantage of the rapid antigen tests is that they can be produced in quantities of millions. And can it be point of care and so and obviously high yield a rapid result. So as with everything else in this emergency, we try to walk a fine line of balancing risks and benefits and understanding the performance of various technologies, trying to address concerns with the certain issues and but the overall objective is trying to make high-quality, accurate testing available in the largest possible way.
SPEAKER QUESTION: Deborah Sigara
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: molecular testing limitations, testing capacity, rapid antigen tests
REVIEW FLAG: False

QA Block 13-2
CLARIFIED QUESTION: What are some alternative ways to do molecular testing that FDA has allowed?
CLARIFIED ANSWER: The FDA allows an expanding number of essay PCR instruments to be used if properly validated, as noted on the FDA's FAQ page. Additionally, CMS provides flexibility for CLIA labs to expand their use of other instruments on campus.
VERBATIM QUESTION: What are some alternative ways to do molecular testing that FDA has allowed?
VERBATIM ANSWER: Unfortunately, CMS has provided some flexibility here. The FDA has provided some flexibility as well in that we've on our FAQ page for alternative ways to do molecular testing, we are allowing an expanding number of essay PCR instruments to be used, properly validated some sort of bridging city by the lab. And CMS has - to my understanding - given the ability to expand a CLIA lab to be able to use other instruments that may be on campus.
SPEAKER QUESTION: Deborah Sigara
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA flexibility for molecular testing, CMS lab expansion flexibility
REVIEW FLAG: False

QA Block 13-3
CLARIFIED QUESTION: What guidance has CMS provided regarding the use of CLIA labs with PCR instruments?
CLARIFIED ANSWER: CMS has provided flexibility in expanding CLIA labs' use of PCR instruments, allowing them to utilize additional instruments available on campus, as long as these are properly validated. Refer to the CMS memo for details.
VERBATIM QUESTION: What guidance has CMS provided regarding the use of CLIA labs with PCR instruments?
VERBATIM ANSWER: Unfortunately, CMS has provided some flexibility here. The FDA has provided some flexibility as well in that we've on our FAQ page for alternative ways to do molecular testing, we are allowing an expanding number of essay PCR instruments to be used, properly validated some sort of bridging city by the lab. And CMS has - to my understanding - given the ability to expand a CLIA lab to be able to use other instruments that may be on campus. So I will just refer you to the CMS memo.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CMS guidance, CLIA labs, PCR instruments
REVIEW FLAG: False

QA Block 13-4
CLARIFIED QUESTION: What is the value of rapid antigen tests and how can their results be properly interpreted?
CLARIFIED ANSWER: Rapid antigen tests, while less sensitive than molecular tests, provide value if their performance and results are properly understood. Positive results can likely be acted upon, whereas negative results may require follow-up with molecular testing to confirm. These tests are advantageous due to their ability to produce quick results in large quantities.
VERBATIM QUESTION: What is the value of rapid antigen tests and how can their results be properly interpreted?
VERBATIM ANSWER: We are very encouraged that there are a number of developers that are developing a rapid antigen test. Now, traditionally have not been as sensitive as molecular tests, that's a known challenge. We have been reaching and discussing tests with stakeholder communities and professional organizations. And although we know that the performance may be less sensitive, say, then a molecular test, there may still be value if users understand the performance of these tests and the proper use of these tests and the proper interpretation and use of results. So for example, some of these rapid tests may be very specific so if you get a positive result in a short amount of time, you can probably act on it. If you get a negative result, you will want to understand what is the sensitivity of the test, what is the potential for a false negative, and use other information that's available to healthcare workers to assess what is the proper follow-up for the patient. Perhaps it's a reflex to a molecular test in the appropriate situations. The advantage of the rapid antigen tests is that they can be produced in quantities of millions. And can it be point of care and so and obviously high yield a rapid result.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Rapid antigen tests, Test interpretation, Testing scale-up
REVIEW FLAG: False

QA Block 13-5
CLARIFIED QUESTION: What are the advantages of rapid antigen tests compared to molecular tests?
CLARIFIED ANSWER: Rapid antigen tests offer advantages such as being producible in large quantities, providing point-of-care capabilities, and delivering rapid results. While less sensitive than molecular tests, they may still have value if their performance characteristics are understood and appropriately utilized.
VERBATIM QUESTION: What are the advantages of rapid antigen tests compared to molecular tests?
VERBATIM ANSWER: We are very encouraged that there are a number of developers that are developing a rapid antigen test. Now, traditionally have not been as sensitive as molecular tests, that's a known challenge. We have been reaching and discussing tests with stakeholder communities and professional organizations. And although we know that the performance may be less sensitive, say, then a molecular test, there may still be value if users understand the performance of these tests and the proper use of these tests and the proper interpretation and use of results. So for example, some of these rapid tests may be very specific so if you get a positive result in a short amount of time, you can probably act on it. If you get a negative result, you will want to understand what is the sensitivity of the test, what is the potential for a false negative, and use other information that's available to healthcare workers to assess what is the proper follow-up for the patient. Perhaps it's a reflex to a molecular test in the appropriate situations. The advantage of the rapid antigen tests is that they can be produced in quantities of millions. And can it be point of care and so and obviously high yield a rapid result.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Rapid antigen test benefits, Comparison with molecular tests
REVIEW FLAG: False

QA Block 13-6
CLARIFIED QUESTION: What additional steps can be taken if a rapid antigen test yields a negative result and a false negative is possible?
CLARIFIED ANSWER: If a rapid antigen test gives a negative result, healthcare workers should consider the test's sensitivity and potential for false negatives. Additional steps like follow-up molecular testing may be warranted based on the clinical situation.
VERBATIM QUESTION: What additional steps can be taken if a rapid antigen test yields a negative result and a false negative is possible?
VERBATIM ANSWER: If you get a negative result, you will want to understand what is the sensitivity of the test, what is the potential for a false negative, and use other information that's available to healthcare workers to assess what is the proper follow-up for the patient. Perhaps it's a reflex to a molecular test in the appropriate situations.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Rapid Antigen Test Sensitivity, False Negatives, Follow-up Molecular Testing
REVIEW FLAG: False

QA Block 13-7
CLARIFIED QUESTION: What are the FDA's guidelines for ensuring timely molecular test results given limited lab capacity?
CLARIFIED ANSWER: The FDA and CMS have provided flexibility to labs, such as authorizing additional validated instruments for molecular testing, to address lab capacity limitations and ensure timely results.
VERBATIM QUESTION: What are the FDA's guidelines for ensuring timely molecular test results given limited lab capacity?
VERBATIM ANSWER: Yes. No, that's a great question and it's a challenging situation. And although we the manufacturers have really done a great job on the molecular test, at least make the PCR readings in high abundance, a lot of high throughput manufacturers have come on to the market with UA authorizations. But even so, the need for testing and the desire for the molecular testing has a tendency to potentially outstrip the lab capacity to, you know, return molecular results in a timely matter for if you really want to expand testing into more populations. So that is definitely a challenge. It's definitely one that we've been thinking about and others in the government have been thinking about how to handle. Unfortunately, CMS has provided some flexibility here. The FDA has provided some flexibility as well in that we've on our FAQ page for alternative ways to do molecular testing, we are allowing an expanding number of essay PCR instruments to be used, properly validated some sort of bridging city by the lab. And CMS has - to my understanding - given the ability to expand a CLIA lab to be able to use other instruments that may be on campus.
SPEAKER QUESTION: Deborah Sigara
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Molecular test capacity, Lab flexibility, Timely results
REVIEW FLAG: False

QA Block 13-8
CLARIFIED QUESTION: How can labs properly validate and bridge additional PCR instruments for molecular testing?
CLARIFIED ANSWER: FDA and CMS have provided flexibility for labs to validate and bridge additional PCR instruments, with guidance available on FDA's FAQ page and in a CMS memo for expanding testing within CLIA labs.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: CMS has provided some flexibility here. The FDA has provided some flexibility as well in that we've on our FAQ page for alternative ways to do molecular testing, we are allowing an expanding number of essay PCR instruments to be used, properly validated some sort of bridging city by the lab. And CMS has - to my understanding - given the ability to expand a CLIA lab to be able to use other instruments that may be on campus. So I will just refer you to the CMS memo.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: PCR instrument validation, CMS flexibility, FDA guidelines
REVIEW FLAG: False

QA Block 13-9
CLARIFIED QUESTION: What flexibility has CMS provided to expand CLIA labs' capacity for molecular testing?
CLARIFIED ANSWER: CMS has provided flexibility by allowing CLIA labs to use additional instruments, and FDA has outlined alternative approaches for molecular testing on its FAQ page.
VERBATIM QUESTION: What flexibility has CMS provided to expand CLIA labs' capacity for molecular testing?
VERBATIM ANSWER: Unfortunately, CMS has provided some flexibility here. The FDA has provided some flexibility as well in that we've on our FAQ page for alternative ways to do molecular testing, we are allowing an expanding number of essay PCR instruments to be used, properly validated some sort of bridging city by the lab. And CMS has - to my understanding - given the ability to expand a CLIA lab to be able to use other instruments that may be on campus. So I will just refer you to the CMS memo.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CLIA lab capacity, CMS flexibility, PCR instruments
REVIEW FLAG: False

QA Block 13-10
CLARIFIED QUESTION: What are the FDA's recommendations for addressing the challenges of less sensitive rapid antigen tests?
CLARIFIED ANSWER: The FDA highlights that while rapid antigen tests are less sensitive than molecular tests, they can be valuable if users understand their performance and use results appropriately. Positive results can often be acted upon, while negatives might require follow-up with molecular tests. These tests can be produced in large quantities and provide rapid results at the point of care.
VERBATIM QUESTION: What are the FDA's recommendations for addressing the challenges of less sensitive rapid antigen tests?
VERBATIM ANSWER: We are very encouraged that there are a number of developers that are developing a rapid antigen test. Now, traditionally have not been as sensitive as molecular tests, that's a known challenge. We have been reaching and discussing tests with stakeholder communities and professional organizations. And although we know that the performance may be less sensitive, say, then a molecular test, there may still be value if users understand the performance of these tests and the proper use of these tests and the proper interpretation and use of results. So for example, some of these rapid tests may be very specific so if you get a positive result in a short amount of time, you can probably act on it. If you get a negative result, you will want to understand what is the sensitivity of the test, what is the potential for a false negative, and use other information that's available to healthcare workers to assess what is the proper follow-up for the patient. Perhaps it's a reflex to a molecular test in the appropriate situations. The advantage of the rapid antigen tests is that they can be produced in quantities of millions. And can it be point of care and so and obviously high yield a rapid result.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Rapid antigen test sensitivity, Guidance on test use, Follow-up testing
REVIEW FLAG: False

QA Block 13-11
CLARIFIED QUESTION: What measures are being taken to make rapid antigen tests available in large quantities quickly?
CLARIFIED ANSWER: FDA is working with rapid antigen test developers to ensure these tests, which can be produced in millions and yield rapid results, are made available soon. Despite challenges like lower sensitivity compared to molecular tests, FDA is balancing risks and working towards making accurate testing accessible.
VERBATIM QUESTION: What measures are being taken to make rapid antigen tests available in large quantities quickly?
VERBATIM ANSWER: We are very encouraged that there are a number of developers that are developing a rapid antigen test. Now, traditionally have not been as sensitive as molecular tests, that's a known challenge. We have been reaching and discussing tests with stakeholder communities and professional organizations. And although we know that the performance may be less sensitive, say, then a molecular test, there may still be value if users understand the performance of these tests and the proper use of these tests and the proper interpretation and use of results. So for example, some of these rapid tests may be very specific so if you get a positive result in a short amount of time, you can probably act on it. If you get a negative result, you will want to understand what is the sensitivity of the test, what is the potential for a false negative, and use other information that's available to healthcare workers to assess what is the proper follow-up for the patient. Perhaps it's a reflex to a molecular test in the appropriate situations. The advantage of the rapid antigen tests is that they can be produced in quantities of millions. And can it be point of care and so and obviously high yield a rapid result. So as with everything else in this emergency, we try to walk a fine line of balancing risks and benefits and understanding the performance of various technologies, trying to address concerns with the certain issues and but the overall objective is trying to make high-quality, accurate testing available in the largest possible way. So hopefully some of those concepts and thoughts are helpful. We are working very hard with some rapid imaging and test developers in order to try to make those available in the not too distant future.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Rapid antigen test production, Testing accessibility, Test sensitivity challenges
REVIEW FLAG: False

QA Block 13-12
CLARIFIED QUESTION: How can users be informed about the performance and proper interpretation of rapid antigen test results?
CLARIFIED ANSWER: Users must understand the sensitivity and specificity of rapid antigen tests, including their potential for false negatives. Positive results can generally be acted upon quickly, but negative results may require follow-up with molecular tests or further assessment by healthcare providers.
VERBATIM QUESTION: How can users be informed about the performance and proper interpretation of rapid antigen test results?
VERBATIM ANSWER: And although we know that the performance may be less sensitive, say, then a molecular test, there may still be value if users understand the performance of these tests and the proper use of these tests and the proper interpretation and use of results. So for example, some of these rapid tests may be very specific so if you get a positive result in a short amount of time, you can probably act on it. If you get a negative result, you will want to understand what is the sensitivity of the test, what is the potential for a false negative, and use other information that's available to healthcare workers to assess what is the proper follow-up for the patient. Perhaps it's a reflex to a molecular test in the appropriate situations.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Rapid antigen tests, Sensitivity and specificity, Interpretation of results
REVIEW FLAG: False

QA Block 13-13
CLARIFIED QUESTION: In which scenarios should negative rapid antigen test results be reflexed to molecular testing?
CLARIFIED ANSWER: Negative rapid antigen test results should be reflexed to molecular testing depending on the sensitivity of the test, the potential for false negatives, and clinical assessment by healthcare workers to determine proper follow-up.
VERBATIM QUESTION: In which scenarios should negative rapid antigen test results be reflexed to molecular testing?
VERBATIM ANSWER: If you get a negative result, you will want to understand what is the sensitivity of the test, what is the potential for a false negative, and use other information that's available to healthcare workers to assess what is the proper follow-up for the patient. Perhaps it's a reflex to a molecular test in the appropriate situations.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: rapid antigen tests, molecular testing, reflex testing
REVIEW FLAG: False

### removed qa blocks
QA Block 1-8
CLARIFIED QUESTION: Where can developers find the template for serological test validation submissions?
CLARIFIED ANSWER: The FDA has provided downloadable serological test development templates for both IVD kit manufacturers and laboratories on its website.
VERBATIM QUESTION: Where can developers find the template for serological test validation submissions?
VERBATIM ANSWER: And one other update is that we did provide serological tests development templates for both IVD kit manufacturers as well as laboratories who develop a test and that is downloadable in editable form to make it easy to use. So please check out our website.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serological test templates, Submission guidance
REVIEW FLAG: False

QA Block 11-2
CLARIFIED QUESTION: Do serology tests like the ones with EUA distinguish between IgG and IgM?
CLARIFIED ANSWER: Some serology tests distinguish IgG and IgM, while others claim a PAN antibody status which detects all antibody isotypes. Tests only partially covering isotypes cannot claim PAN antibody status.
VERBATIM QUESTION: Do serology tests like the ones with EUA distinguish between IgG and IgM?
VERBATIM ANSWER: Yes. So there's different flavors. So some test, let's say we are going to look at IgG and were going to look at IgM, there is other claims such as PAN anti-body. We expect a test that has been developed for PAN anti-body will be able to detect all of the isotypes. And then there are others that may only partially cover some of the isotypes, so they cannot claim PAN antibody tests. And so that's Nuance language is good pickup and we seek to have truth in advertising as it comes to a test name and a test target. Hopefully that's helpful.
SPEAKER QUESTION: Julie Leslie
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology tests, IgG and IgM distinction, PAN antibody
REVIEW FLAG: False

QA Block 12-5
CLARIFIED QUESTION: How should developers of 3D printed swabs seek specific feedback from the FDA outside of this Town Hall?
CLARIFIED ANSWER: Developers of 3D printed swabs should email COVIDManufacturing@fda.hhs.gov for specific feedback on submissions to the FDA.
VERBATIM QUESTION: How should developers of 3D printed swabs seek specific feedback from the FDA outside of this Town Hall?
VERBATIM ANSWER: Yes, this may be in regards to a specific situation that the agency is reviewing. So I would just direct the question back to our COVIDManufacturing@fda.hhs.gov email address for specific feedback on anything that you may have submitted to the FDA. We are very interested in new technologies to address shortages are potential shortages. And the 3D swabs are part of that. But if there is a specific swab, specific developer of a swab or specific question about such swabs, I'm probably not going to be able to answer it on the call today. But our team can hopefully answer that question for you in short order.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: 3D printed swabs, Submitting inquiries to FDA, COVID-19 diagnostics
REVIEW FLAG: False


### extract log
#### extract log header
datetime: 2024-12-31 13:15:17 UTC-08:00 America/Los_Angeles
source file prep: primary.llm.add_transcript_section_delimiters for non-FDA speakers
ROUND 1 NAME: Explicit Questions Extraction
- prompt: FCALL_SYSTEM_PROMPT_QA_QONLY_EXPLICIT_1D
- tools: tools_qa_qonly_explicit_1
- provider: openai
- model: gpt-4o-2024-11-20

#### Section 1 of 13
##### Explicit Questions Extraction

##### Implicit Questions Extraction
QI 1-1: What are the details of the FDA's updated antibody test policy for commercial manufacturers?
QI 1-2: What validation and performance expectations must be submitted for serological tests under the new policy?
QI 1-3: What is the timeline for submitting emergency use authorization requests for antibody tests under the new guidance?
QI 1-4: What changes were made to the regulatory flexibility originally provided to serological test developers?
QI 1-5: What are the specific performance thresholds for sensitivity and specificity for serological tests going forward?
QI 1-6: What are the FDA's recommendations for confirmatory serological testing when specificity is a concern?
QI 1-7: What factors will the FDA consider in making regulatory determinations for serological tests, including data sources?
QI 1-8: Where can developers find the template for serological test validation submissions?
QI 1-9: What new updates did the FDA add to the FAQ page regarding molecular testing and the screening of asymptomatic individuals?
QI 1-10: What steps should developers take if they want to validate tests for broader screening of asymptomatic populations?
QI 1-11: Where can developers find the serological test development templates provided by the FDA?
QI 1-12: What is the purpose of the new FDA calculator for estimating test performance, and how can it be used effectively?

#### Section 2 of 13
##### Explicit Questions Extraction
QE 2-1: Do you agree or disagree with the approach described in my comments regarding ease of use and human factors testing?
QE 2-2: What is your position on using simulated use assessments where users simulate certain actions, such as administering a finger stick, instead of using real samples in human factors testing?

##### Implicit Questions Extraction
QI 2-1: What level of alignment exists between the FDA's various teams, such as the human factors group, regarding guidance for home-based COVID-19 diagnostics?
QI 2-2: Will the upcoming template for home collection address specific usability data requirements for these tests?
QI 2-3: How does the FDA plan to ensure accuracy and safety for home-based COVID-19 testing during the emergency use period?
QI 2-4: Does the FDA consider simulated use assessments sufficient for validating certain types of human factor elements in diagnostics, like instructions for use or finger stick administration?
QI 2-5: What justifies the FDA's current preference for performance data involving actual patients or simulated patients over alternative assessment methods?

#### Section 3 of 13
##### Explicit Questions Extraction
QE 3-1: Does the FDA object to the use of IVDD serology antibody rapid tests outside of a laboratory by health care professionals?
QE 3-2: Am I understanding correctly that places like doctor's offices or urgent care clinics without a CLIA license cannot use point-of-care rapid tests?
QE 3-3: At this point, is there any objection from the FDA for the use of these devices outside of the CLIA sphere?

##### Implicit Questions Extraction
QI 3-1: Does the FDA view tests without EUA authorization as automatically designated for high-complexity lab use?
QI 3-2: What is the FDA's process for determining whether a point-of-care test can be used outside of moderate- or high-complexity labs?
QI 3-3: Are there any specific FDA regulatory requirements for point-of-care or near-patient tests to be performed without a CLIA waiver?
QI 3-4: Does the FDA allow for home use of tests without specific authorization?
QI 3-5: Does FDA require laboratories to verify and validate tests that have not been reviewed prior to use?
QI 3-6: Does CMS allow rapid certification of new CLIA-waived sites in the US?
QI 3-7: What is the FDA's role in determining whether a test can be a waived test or a deemed waived test?

#### Section 4 of 13
##### Explicit Questions Extraction
QE 4-1: What is the relationship of the umbrella pathway to the guidance issued on May 4?
QE 4-2: Can a manufacturer send 125 test kits to the NCI to jumpstart the voluntary testing program while also working on either a pre-EUA or EUA?
QE 4-3: Does the pre-EUA pathway still exist?

##### Implicit Questions Extraction
QI 4-1: How should saliva samples be validated for serological or direct antigen tests?
QI 4-2: Are templates available with specific recommendations for validating saliva as a sample type?
QI 4-3: What validation steps might make the use of NCI resources unnecessary or less critical?
QI 4-4: What criteria does the FDA use to decide if NCI testing is warranted?
QI 4-5: What are the limitations of the umbrella pathway concerning sample types like whole blood or finger-stick?
QI 4-6: Can the umbrella pathway be used for tests designed for home testing or home collection?
QI 4-7: What additional studies are recommended for tests outside the narrow uses supported by the umbrella pathway?

#### Section 5 of 13
##### Explicit Questions Extraction
QE 5-1: How should manufacturers manage results from testing with NCI while meeting the requirement to submit an EUA by May 18?

##### Implicit Questions Extraction
QI 5-1: What is the process for FDA to use NCI data in the EUA decision-making?
QI 5-2: If a primary reviewer has not been assigned, how should developers contact the FDA for updates on their test submissions?
QI 5-3: Does the updated guidance issued on Monday affect the ability of test developers to notify the FDA and market their tests while awaiting EUA approval?
QI 5-4: Can developers market their tests during the FDA review process if they submit an EUA application within the 10-day notification period?

#### Section 6 of 13
##### Explicit Questions Extraction
QE 6-1: If a developer is considering the umbrella pathway, could FDA Townhall provide characterization data for the NIH stamp holder being used to help developers understand the level of characterization of the samples?

##### Implicit Questions Extraction
QI 6-1: What reference methods are used by the inter-agency group to confirm the presence or absence of IgM or IgG in samples?
QI 6-2: Are negative samples used in FDA characterization pre-COVID-19, and how is their history of exposure to other pathogens documented?
QI 6-3: How does the FDA maintain consistency (harmonization) when transitioning from one batch of samples to another in the umbrella pathway?
QI 6-4: Does the rigorous characterization of positive and negative samples simplify the validation process for developers using the umbrella pathway?
QI 6-5: Does the FDA believe that characterized samples under the umbrella pathway ensure high performance for diagnostic counts?
QI 6-6: What feedback mechanism exists for developers if they perceive the sample characterization in the umbrella pathway as a disadvantage?

#### Section 7 of 13
##### Explicit Questions Extraction
QE 7-1: How many test kits would be required for submission to the NCI for evaluation, such as for the "You're Immune" test?
QE 7-2: Should manufacturers going through NCI validation still submit an EUA application at the same time or wait for the umbrella pathway?

##### Implicit Questions Extraction
QI 7-1: What information should be included in an EUA application if the test manufacturer is also submitting tests for NCI evaluation?
QI 7-2: How does the FDA determine capability and instrumentation needs for testing non-lateral flow devices as part of the NCI evaluation?
QI 7-3: What are the requirements for submitting test kits to the FDA that do not fall under the lateral flow category?

#### Section 8 of 13
##### Explicit Questions Extraction
QE 8-1: What are the authorized settings for use of serology lateral flow tests that do not have an EUA?
QE 8-2: Why isn't it more clear in FDA guidance that only highly complex laboratories can run certain tests without an EUA?
QE 8-3: Can serology lateral flow tests only be used in highly complex laboratories until an EUA is issued and a complexity designation is made?
QE 8-4: Are highly complex facilities able to perform point of care testing under their certification?

##### Implicit Questions Extraction

#### Section 9 of 13
##### Explicit Questions Extraction
QE 9-1: Is FDA considering deferring to states on the issue of access to COVID-19 testing instead of maintaining the RX-only requirement?
QE 9-2: Does FDA have specific tenets or guidance regarding authorization of COVID-19 testing for non-prescription use?
QE 9-3: Is FDA expecting to see differences among different types of asymptomatic patients in terms of test performance?
QE 9-4: What is driving the need for further validation to support general crowd testing?

##### Implicit Questions Extraction
QI 9-1: Are there any existing FDA guidelines or FAQ updates regarding new models for addressing the RX-only requirement for test ordering?
QI 9-2: What kind of data would the FDA require to support claims for COVID-19 diagnostic tests specifically designed for asymptomatic populations?
QI 9-3: Is the FDA open to revising the definition of "suspected COVID-19" to include asymptomatic individuals within their intended use criteria without further validation?
QI 9-4: What specific swab or sample types does the FDA currently recommend or anticipate might be suitable for asymptomatic COVID-19 testing?
QI 9-5: How does the FDA define sufficient evidence to validate a diagnostic test for asymptomatic carriers of SARS-CoV-2?

#### Section 10 of 13
##### Explicit Questions Extraction
QE 10-1: Have you consolidated the type sequences that are in molecular tests?
QE 10-2: Have you consolidated the information about the protein components included in serology tests?

##### Implicit Questions Extraction
QI 10-1: What are the proprietary limitations regarding sharing gene target information for molecular tests?
QI 10-2: What details about serology test antigens should be made publicly available?
QI 10-3: What viral or protein targets should be identified for direct antigen tests to aid comparative studies and research?
QI 10-4: Are there any restrictions on developers sharing primers and probes with the community?
QI 10-5: Does the FDA have any recommendations for how test developers should make antigen information accessible?

#### Section 11 of 13
##### Explicit Questions Extraction
QE 11-1: What is the difference between serology antibody tests with EUA and total antibody tests?
QE 11-2: Do serology tests like the ones with EUA distinguish between IgG and IgM?

##### Implicit Questions Extraction
QI 11-1: What are the FDA expectations for PAN antibody tests?
QI 11-2: How should developers label serology tests that detect only some isotypes?
QI 11-3: What does the FDA mean by 'truth in advertising' for test names and targets?

#### Section 12 of 13
##### Explicit Questions Extraction
QE 12-1: What is the progress on the FDA's review of 3D printed swabs based on the information provided?
QE 12-2: Are there general questions about 3D swabs that can be addressed today?

##### Implicit Questions Extraction
QI 12-1: What specific technical considerations for 3D printed swabs does the FDA plan to provide to the community?
QI 12-2: What is the timeline for the release of updated technical guidelines related to 3D printed swabs?
QI 12-3: How should developers of 3D printed swabs seek specific feedback from the FDA outside of this Town Hall?
QI 12-4: Who should developers contact within the FDA to track the progress of their submissions on 3D printed swabs?

#### Section 13 of 13
##### Explicit Questions Extraction
QE 13-1: How can molecular testing not be used for the general population when it is used for contact tracing?
QE 13-2: What are some alternative ways to do molecular testing that FDA has allowed?
QE 13-3: What guidance has CMS provided regarding the use of CLIA labs with PCR instruments?
QE 13-4: What is the value of rapid antigen tests and how can their results be properly interpreted?
QE 13-5: What are the advantages of rapid antigen tests compared to molecular tests?
QE 13-6: What additional steps can be taken if a rapid antigen test yields a negative result and a false negative is possible?

##### Implicit Questions Extraction
QI 13-1: What are the FDA's guidelines for ensuring timely molecular test results given limited lab capacity?
QI 13-2: How can labs properly validate and bridge additional PCR instruments for molecular testing?
QI 13-3: What flexibility has CMS provided to expand CLIA labs' capacity for molecular testing?
QI 13-4: What are the FDA's recommendations for addressing the challenges of less sensitive rapid antigen tests?
QI 13-5: What measures are being taken to make rapid antigen tests available in large quantities quickly?
QI 13-6: How can users be informed about the performance and proper interpretation of rapid antigen test results?
QI 13-7: In which scenarios should negative rapid antigen test results be reflexed to molecular testing?
